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Transfection and direct conversion, which is referred to as “transdifferentiation” in this thesis, 
play significant roles in regenerative medicine research including gene therapy, vaccines, modeling of 
diseases and disorders, drug testing, cell replacement therapy, and tissue engineering. Most of this 
research has depended on the use of viral vectors, which can be associated with adverse conditions such 
as genotoxic integration of viral payloads and immunogenicity. Non-viral vectors have the potential to 
eliminate these problems and have added benefits such as ease of production and targetability, however, 
they come at the cost of efficiency. Substrates topographies are known to be able to modulate cell 
behaviors including efficiency of non-viral transfection and non-viral transdifferentiation. However, 
current research is limited to only a few combinations of cell type, substrate material, and topographical 
geometry. In this thesis, we specifically investigated the hypotheses that nano- or micro-topographical 
PDMS substrates would be able to increase non-viral transfection efficiency and/or enhance non-viral 
neuronal transdifferentiation of human mesenchymal stem cells (hMSCs). We screened the effects of 16 
different nano- and micro-scale topographies, with different geometries, on both processes. Results from 
our transfection study showed that five of the topographical patterns, which included nano- and micro-
gratings, concave micro-lenses, micro-holes, and nano-pillars, increased the efficiency of Lipofectamine-
mediated transfection. However, these results were not statistically significant, so further rigorous study 
of these selected topographies is needed. Convex and concave micro-lenses interestingly showed opposite 
effects on transfection efficiency, and are suggested for further study to investigate the significance of the 
relationship between direction of lens curvature and transfection efficiency. Our studies on 
transdifferentiation were neither able to confirm or disprove our hypothesis. No neuronal morphology was 
seen in samples that went through the transdifferentiation procedure. Immunofluorescent staining for the 
neuronal lineage marker, microtubule-associated protein 2 (MAP2), showed weak fluorescence in all 
samples including negative controls. This could have been due to non-specific staining or weak MAP2 
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expression previously shown to exist in hMSCs without any induction. We found that the hMSCs became 
over 95% confluent during the transdifferentiation procedure which may have interfered with the 
transfections or topography-cell interactions during the transdifferentiation procedure. We also found that 
the poly(amido amine) transfection reagent used during the transdifferentiation procedure was more toxic 
to hMSCs than, as reported elsewhere, to mouse embryonic fibroblasts or COS-7 cells. Together these 
observations indicate that parameters affecting cell confluence (such as seeding density or length of 
transfection phase) and the specific non-viral transfection reagent used should be reconsidered for future 
work on neuronal transdifferentiation of hMSCs. Alternatively, since the neuronal transdifferentiation 
procedure has previously been shown to work on fibroblasts, investigations of topographical influence on 
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 This thesis project was developed as a result of the interest in generating relevant cell types that 
can be used in regenerative medicine, modeling of diseases and disorders, and drug testing. In 
regenerative medicine, specific cell types are important for use in cell therapies where they are delivered 
into a site of injury to integrate and replace damaged tissue or to release signaling factors that can 
promote self-healing of the damaged tissue. Regenerative medicine also makes use of specific cell types 
in tissue engineering to create tissue mimics that can be used to replace or repair diseased tissue and 
sometimes full organs1. In disease and disorder modeling, specific cell types can be used to demonstrate 
specific processes that occur in affected tissues to further understand how the conditions develop and for 
testing potential treatments2. 
While some specific cell types can be harmlessly taken from the body and expanded for further 
use, some clinically relevant cell types such as cardiomyocytes, neurons, pancreatic cells, and hepatocytes 
cannot3. This is due to their low regenerative capacity in vivo or inability to proliferate in vitro. These cell 
types must therefore be generated starting from a different cell type. Furthermore, it can be beneficial to 
produce cells from a specific patient creating an ideal genetic match. For these reasons, it is beneficial to 
begin with an accessible source of starting material, like cells from skin or bone marrow, and convert 
these cells into the desired cell type. 
This project focuses on the development of induced neurons (iNs), which are cells artificially 
derived from somatic cells that exhibit neuronal morphology, neuron-specific gene products, and 
functional properties of neurons4, 5. According to the World Health Organization, neurological disorders 
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affect up to one billion people worldwide6. This includes neurodegenerative diseases, such as Alzheimer’s 
disease and Parkinson’s disease, as well as other disorders including stroke6. For these neurodegenerative 
diseases and for many neurological disorders including autism spectrum disorders, there are currently no 
long-term cures and there is a lack of means to understand their physiopathology. As a result, there is a 
demand for an appropriate neuronal cell source for cell-replacement therapy and cellular modeling. Due 
to low regenerative capacity in the body, neurons cannot be transplanted or explanted from donors or 
from the living tissue of a patient; they must be created from other cells types. Current methods for 
generating neurons from other cell types include differentiation of embryonic stem cells or differentiation 
of induced pluripotent stem cells, however these methods are tedious7 8, have ethical issues9, and can be 
tumorigenic10. Therefore, an appealing solution is to use transdifferentiation, which is the direct 
conversion of one somatic cell type to another8. This approach eliminates ethical issues, reduces the time 
needed to generate the final cell type, and eliminates the use of tumorigenic stem cells.  
Researchers have developed ways to generate mouse and human induced neuronal cells from 
accessible and expendable cell types by transdifferentiation11, 12. However, they have typically been 
carried out using viral vectors to deliver nucleic acids to the cells8. The use of viral vectors is associated 
with adverse conditions such as genotoxic integration of viral payloads and immunogenicity, limiting the 
acceptance of these methods into clinical practice13 14. Non-viral transdifferentiation has also been used to 
convert mouse cells into induced neuronal cells, however the efficiency of this conversion was very low 
(7.6%) 15. Human cells are even more difficult to convert8, 12. Therefore, increasing efficiency of non-viral 
methods is necessary. 
Micro- and nano-topographical surfaces have been shown to be able to increase non-viral 
transfection efficiency16, 17 and to influence cells towards the neuronal lineage18-20. Our objective is to 
investigate the influence of micro- and nano-topography on enhancing non-viral transfection and neuronal 
transdifferentiation of human mesenchymal stem cells (hMSCs) from bone marrow. 
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1.2. Differentiation, Reprograming, and Transdifferentiation 
 
Differentiation, reprogramming, and transdifferentiation are all possible routes that may be taken 
to switch one cell type into a different cell type. The route selected for cell switching is dependent on the 
desired cell type and application.  
Cells used in clinical applications that are intended to be placed into a patient or induced in vivo, 
have the most requirements to meet. Ideally these cells would originate from the patient’s own body to 
reduce the risk of immune rejection and would avoid pluripotency to avoid the risk of being tumorigenic 
8. Also, ideally their induction would be fast, safe, and efficient. While methods have been developed 
which meet some of these requirements, it has been challenging to find a single method that meets all of 
these ideal characteristics. In this pursuit, there has been a wealth of research conducted on methods of 
cell switching.  
 Differentiation is the process by which a less specialized cell develops or matures to become 
more distinct in form and function21. The use of differentiation became highly relevant to regenerative 
medicine in 1981 when mouse embryonic stem cell (ESC) lines were established and in 1998 when the 
first human ESC lines were created 22-24. ESCs can be used to derive any cell type of the three germ layers 
through differentiation. However, a major limitation of using ESCs is that to create ESCs, human 
embryos have to be destroyed. Other major concerns are that cells derived from ESCs have a risk of being 
tumorigenic due to ESC pluripotency and have a risk of immunogenic rejection after implantation due to 
genetic dissimilarity to patients25, 26.  
 The second type of cell switching involves reprograming, which is the conversion of a 
somatic cell type to an induced pluripotent stem cell (iPSC). Motivated by the discovery of human ESCs, 
and to avoid the ethical issues associated with ESCs, researchers discovered in 2006 that mouse 
fibroblasts could be reprogrammed into iPSCs and in 2007 human iPSCs were successfully produced 27 28. 
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Similar to ESCs, iPSCs can be used to derive any cell type of the three germ layers through 
differentiation. iPSCs can also be made out of a patient’s own cells, thus genetically matching the patient 
and reducing the risk of rejection after implantation. However, the serious concern of tumorigenicity 
remains, limiting clinical applicability of cells derived from iPSCs29.  
 Finally, transdifferentiation is defined as the conversion of one cell type to another30. One type of 
transdifferentiation is the conversion of somatic cells into another lineage without going through an 
intermediate proliferative pluripotent stem cell stage8, which has been referred to as “direct conversion” 
in the literature. The conversion of somatic cells into another cell type can be induced by two different 
approaches8. One of them is by overexpression of lineage-specific factors11, 31-37. This approach generates 
terminal cells without going through pluripotency or multipotency38. The other approach is by transient 
expression of the Yamanaka factors to propel the cells toward an epigenetically unstable state (no 
pluripotency), before directing them toward the target cell lineage39-41. This approach generates 
multipotent precursor cells without going through pluripotency, however it does involve the transient 
opening of multipotent pathways38. In this thesis project we investigated direct conversion, which is 
referred to as “transdifferentiation” throughout the thesis.  
The first instance of induced transdifferentiation was reported in 1987, when mouse fibroblasts 
were transfected with a single transcription factor (TF), MyoD, which converted them into myoblasts31. 
This discovery occurred well before the discovery of iPSCs, however, recently interest in studying 
transdifferentiation as a means to acquire valuable cell types has grown due to the challenges caused by 
using iPSCs. This method avoids passing cells through a pluripotent teratoma-forming state, and reduces 
the number of steps needed to arrive at the final cell type. Without the need to reprogram cells and 
differentiate them again, direct conversion can decrease the time required for the full process to take 
place, which could be of high importance in clinical applications where a patient must wait for the cells. 
Additionally, with fewer steps in the process, there is less opportunity for compounding loss of efficiency 
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in the conversion. Transdifferentiation has great promise as a tool for producing cell types needed in 
regenerative medicine, disease modeling, and drug testing.  
 
1.3. Methods of Inducing Neuronal Transdifferentiation 
 
Within the past 10 years, transdifferentiation has emerged as one of the preferred strategies to 
develop specific cells types for medical applications42. Method development has gotten quite a bit of 
attention but is still an active area of research as researchers strive to improve safety and efficiency of the 
conversion processes and safety of the final induced cells for use in clinical applications. The methods 
that have been researched include use of TFs, microRNA, and small molecules which can be delivered to 
cells to induce conversion.  
Transdifferentiation induced by TFs or microRNA is often classified further into viral and non-
viral methods which refer to the methods used to deliver the nucleic acids (TFs or microRNA) into the 
cells. Both viral and non-viral methods have benefits and limitations. Viral methods have been most 
widely used, are better understood, and have high transfection efficiency. Non-viral methods may be 
more clinically relevant by addressing the safety concerns tied to viral methods including genotoxic 
integration of viral payloads and immunogenicity. Transdifferentiation by small molecules doesn’t require 
a carrier since small molecules can freely diffuse into cells, but small molecules have mostly been studied 
in the context of being used in combination with TFs or microRNA. This thesis focuses on the use of TFs, 





1.3.1. Transdifferentiation by Delivery of Transcription Factors 
 
The most popular way to achieve transdifferentiation is by delivery of genes encoding TFs43. TFs 
are proteins that regulate the gene expression in a cell by controlling the rate of transcription of DNA into 
messenger RNA (mRNA) by binding to specific DNA sequences44. Abnormal overexpression of certain 
TFs or combinations of TFs can cause one cell type to transition into a different cell type43. There are two 
types of TFs that can be used to induce transdifferentiation. The first is lineage-specific TFs which, during 
natural development, regulate cell-type-specific gene expression patterns. The first example of induction 
of transdifferentiated cells used a lineage-specific TF31. It is thought that when inducing 
transdifferentiation, lineage-specific TFs activate salient features of the target cell type and auto-
regulatory activation of downstream TFs reinforce expression of cell-fate-determining genes, leading to 
an induced stable transcriptional program35. However, this mechanism is hypothetical and has not been 
proven. The second type of TFs are pluripotency TFs. Transient expression of pluripotency TFs can 
create an epigenetically unstable state which can then be more easily influenced towards the desired cell 
type by supplying exogenous inductive signals45. 
Investigations into inducing neuronal transdifferentiation by TFs started by studying the 
conversion of mouse fibroblasts to neuronal cells. The first research paper documenting neuronal 
transdifferentiation was published in 2010 and achieved direct conversion of mouse fibroblasts to 
functional induced neurons (iNs) by use of lineage-specific TFs35. In this study, 19 genes that were known 
to be specifically expressed in neural tissue, known to play important roles in neuronal development, or 
previously used in epigenetic reprograming were screened to find the most successful combination for 
inducing cell conversion. It was found that the combination of Brn2, Ascl1, and Myt1l (BAM) could 
produce mature iNs with the highest efficiency. Mouse embryonic fibroblasts (MEFs) and tail tip 
fibroblasts (TTFs) were harvested from TauEGFP knock-in mice, which are genetically modified so that 
enhanced green fluorescent protein (EGFP) is selectively expressed in neuronal cells, which allowed them 
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to carefully ensure exclusion of neuronal cells from their initial MEF and TTF populations and identify 
cells converted to the neuronal linage. The TF genes were cloned into doxycycline-inducible lentiviral 
vectors. Cells were infected overnight, then cultured in MEF media with doxycycline for 48 hours, and 
then transferred into N3 neuronal induction media with doxycycline. After viral BAM transfection, iNs 
from MEFs expressed microtubule-associated protein 2 (MAP2) and synapsin neuronal markers, and 
those induced from TTFs expressed TauEGFP, Tuj1, NeuN, and MAP2 neuronal markers. This study 
estimated the conversion efficiency by dividing the number of Tuj1-positive cells per area by the number 
of cells initially plated per area. This calculation was validated by the observation that iNs become 
postmitotic, and therefore stop dividing, 24 hours after transgene activation. They reported conversion 
efficiencies of up to 19.5% using BAM factors and lentiviral delivery. The iNs showed functional 
neuronal properties such as action potentials and functional synapses. This discovery inspired researchers 
to investigate whether other combinations of TFs could generate specific neuronal phenotypes for disease 
modeling and whether this method could be used on human cells to generate patient-specific neurons for 
cell therapy. A following study validated the principle of using iNs for modeling autism-spectrum 
disorder46. Their primary objective was to determine whether iNs produced from a mutated organism 
would have the same phenotype as the endogenous neurons of that organism. They directly converted 
MEFs from mice with autism-spectrum disorder-associated point mutation R704C and MEFs from 
littermate wild type (WT) mice into iNs. These mice were also designed to express EGFP at the 
endogenous tau gene locus. The transdifferentiation was carried out by transduction of BAM factors with 
doxycycline-inducible lentiviral vectors as previously described. MEFs transdifferentiated into iNs 
reproduced the phenotype caused by the autism-associated mutation. The conversion efficiencies from 
R704C and WT MEFs were 18.2% and 20.4% respectively, as measured by the fraction of cells that 
activated the TauEGFP reporter. These findings gave evidence that iNs transdifferentiated from non-
neuronal cells can be used to examine neuropsychiatric diseases.  
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To advance this research, neuronal transdifferentiation by delivery of TFs was investigated on 
human cells. There are many differences in the gene regulatory networks of mouse and human neural 
development, therefore the induction of human neuronal transdifferentiation was unlikely to use the same 
method as mouse cells. It was shown that when three independent primary human fetal fibroblast (HFF) 
lines were transduced with BAM factors, in the same manner as the mouse studies35, they did induce cells 
with immature neuronal morphologies and expressing Tuj1, however these cells were functionally 
immature12. Twenty additional factors were screened for one that could improve the generation of human 
iNs using the BAM factors. NeuroD1 was found to improve the efficiency two to three fold after three 
weeks. Conversion efficiencies of HFFs and human postnatal fibroblasts (HPFs) to iNs by BAM factors 
and NeuroD1 (BAMN factors) were similar, ranging from 2-4% of cells seeded. Human iNs were able to 
generate action potentials and many could mature to form synaptic contacts when co-cultured with 
primary mouse cortical neurons. These methods could hopefully lead to generation of patient-specific 
neurons for in vitro disease modeling or regenerative medicine. 
When transplanted into a host, iN cells have poor survival and function because of their limited 
ability to proliferate. Therefore, neuronal restricted progenitors (NRPs) may be a more beneficial cell type 
for neuron replacement therapy to treat neurodegenerative diseases, because they have the ability to 
proliferate, migrate, and develop into neurons. A more recent study made use of TFs to induce direct 
conversion of human fibroblasts into NRPs47. They investigated a group of eight TFs, known to either 
convert fibroblasts into stem cells with proliferative features, promote fibroblasts to acquire neural 
progenitor characteristics, or give induced cells the capacity to become neurons. It was found that Sox2, 
c-Myc, and either Brn1 or Brn4 (which were interchangeable), delivered by lentivirus, could directly 
convert HFFs into human induced NRPs (hiNRPs). These hiNRPs had neuronal morphology, showed 
expression of multiple neuronal markers, and had self-renewal capacity. Additionally, they could be 
differentiated into various terminal neurons with functional membrane properties. These hiNRPs could 
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have potential to be used for neuronal developmental studies as well as therapeutic strategies for 
neurodegenerative diseases.  
Various specific neuronal subtypes and other cell types of the nervous system have also been 
induced by viral delivery of TFs. For example, there have been efforts in producing dopaminergic 
neurons, the cell type lost in Parkinson’s disease. Transduction, using doxycycline-inducible lentiviral 
vectors, was used to deliver lineage-specific transcription factors that act during brain development, 
Ascl1, Nurr1, and Lmx1a, in order to induce transdifferentiation of mouse and human fibroblasts into 
dopaminergic neurons11.  MEFs were converted to induced dopaminergic neurons with a conversion 
efficiency of around 18%. Induced dopaminergic neurons were obtained from human fetal fibroblasts and 
adult fibroblasts with conversion efficiencies of around 6% and 3%, respectively. It was also reported that 
the cells did not pass through any detectable intermediate neuronal stages. In another study, dopaminergic 
neurons were induced by lentiviral delivery of Lmx1a and FoxA2, two genes involved in dopamine 
neuron generation, along with the BAM factors 36. Motor neurons could be induced from MEFs with 
between 5% and 10% efficiency, by forced expression of seven TFs including BAM factors, Lhx3, Isl1, 
Hb9, and Ngn2, delivered by retroviral transfection48. They also found that these fibroblasts did not go 
through a neural progenitor state on their way to becomig motor neurons. When NEUROD1 was added as 
an eighth TF, retroviral transfection of human embryonic fibroblasts could generate human motor 
neurons, but with conversion efficiency under 1%. Finally, myelinogenic oligodendrocyte progenitor cells 
were induced by delivery of eight TFs, Myrf, Myt1, Nkx2.2, Olig1, ST18, Nkx6.2, Olig2, and Sox10, to 
MEFs by lentiviral transfection49. However the conversion efficiency was around 1%. The same 
phenotype could be achieved with a subset of three TFs, Sox10, Olig2, and Nkx6.2, however the 
conversion efficiency was even lower. 
Because of safety concerns restricting the clinical use of viral delivery systems, the development 
of non-viral methods is actively under investigation13. The first non-viral neuronal transdifferentiation 
study was published in 2012. It was shown that primary mouse embryonic fibroblasts (PMEFs) could be 
10 
 
transdifferentiated into neuronal cells by non-viral delivery of the BAM factors using a bioreducible 
linear poly(amido amine)15. Repeated dosing was used to sustain a high level of the transgenes which was 
essential for successful transfection. An efficiency of 7.6% conversion to Tuj1+ cells relative to the 
number of PMEFs seeded was reported. Further increase in efficiency may be necessary to apply this 
method to more resistant adult human cells. In a recent study, a triboelectric simulator (TES) was used in 
conjunction with poly(β-amino ester) (PBAE) transfection of genes encoding BAM TFs to enhance the 
non-viral conversion efficiency of PMEFs to iN cells50. The in vitro conversion induction began with 
BAM transfection by electroporation followed by cell seeding. Two days after, the cells were transfected 
a second time using C32-122 poly(β-amino ester) nanoparticles. Starting on day 3, the PMEF medium 
was replaced with neuronal induction medium and cells were exposed to the TES for 60 min/day each 
day. Conversion efficiency was calculated as the percentage ratio of Tuj1-positive cells to total number of 
cells seeded. On days 12-14, conversion efficiency was 6.41% without TES, and 14.17% when TES was 
used following transfection. Their in vivo study using mice involved injections of BAM TF/poly(β-amino 
ester) polyplex into mouse dermal fibroblasts followed by use of electrocardiogram patches to expose the 
injection sites to TES for 30 min/day for 14 days. Conversion efficiencies were measured to be 0.04% and 
5.86%, with and without exposure to TES respectively. 
 
1.3.2. Transdifferentiation by Delivery of MicroRNA or Small Molecules 
 
 MicroRNAs are short non-coding RNAs that bind to complementary pieces of mRNA after 
transcription and inhibit their translation. In this way, they can inhibit expression of specific genes which 
have influence over cell type. They have potential benefits in comparison to the use of TFs43. For 
example, they can be obtained by chemical synthesis reducing the risk of mutation and their small size 
allows multiple microRNAs to be delivered in the same vector. MicroRNAs have been shown to enhance 
transdifferentiation by TFs and to induce transdifferentiation alone. Direct conversion of human postnatal 
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fibroblasts to iNs has been achieved by delivery of a combinations microRNAs and TFs with conversion 
efficiency of up to  ~10 % 51, 52. Human fibroblasts have also been converted to striatal spiny neurons, the 
primary cell type affected in Huntington’s disease, with a combination of microRNAs and TFs53. Finally, 
microRNAs alone have induced neuronal conversion of human fibroblasts but transfection efficiencies 
were very low (around 1%)52. All of these studies used viral vectors.   
Small molecules (SMs) are defined as being chemical compounds with a low molecular weight54. 
Small molecules that target signaling pathways, epigenetic modifications, or metabolic processes can 
regulate cell development, fate, and function54. Major benefits in using small molecules, instead of TFs or 
microRNAs, are that there is no need to use a delivery vector and no involvement of transgenes. This 
reduces the complexity of the transdifferentiation process and eliminates safety and efficiency concerns 
caused by the use of delivery vectors and transgenes. Additional benefits include cost-effectiveness and 
easy synthesis54. Some studies have shown successful neuronal induction of human and mouse fibroblasts 
by small molecules alone55-57 , however, most often small molecules have been used as additional 
components to enhance transdifferentiation driven by viral delivery of transgenes58, 59.  
 
1.3.3. Comparison of Conversion Efficiencies across Methods for Neuronal Transdifferentiation 
 
In Table 1 we compare the conversion efficiencies achieved with various methods of 
transdifferentiation. The approximation commonly used for reporting conversion efficiency of neuronal 
transdifferentiation was established in the first study showing induced neuronal transdifferentiation, and 
has been widely accepted since then35. Typically this is the number of Tuj1+ cells over the number of 
cells initially seeded, however, in some studies one or more different neuronal marker(s) may be 
considered along with or instead of Tuj1. Sometimes, the neuronal purity of the final cell culture is 
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reported in addition to or instead of the actual conversion efficiency (these values were not included in 
Table 1). 
Another critical factor that should be considered when comparing methods of inducing 
transdifferentiation is their safety for clinical applications. This includes considering whether final 
induced cells are safe to be implanted after in vitro conversion, or whether the conversion can safely take 
place inside a patient when using in vivo conversion.  
Table 1 Comparison of Methods and their Conversion Efficiencies in Neuronal Transdifferentiation. Values are from in 
vitro studies. 
Method Conversion Efficiency 
(%) 
Clinical Applicability Ref. 
Average Highest 
Viral Delivery of TFs (Mouse) 19.4 20.4 Limited by safety of transgene 
delivery strategies 
35 46     
Viral Delivery of TFs (Human) ~3 ~3 Limited by safety of transgene 
delivery strategies 
12   
Non-viral Poly(amido amine) Delivery of TFs 
(Mouse) 
7.6 7.6 Promising, but limited by 
conversion efficiency 
15  
Non-viral Electroporation & Poly(β-amino 




14.17 Promising, but limited by 
conversion efficiency  
 50   
Viral Delivery of MicroRNAs and TFs 
(Human) 
9 10 Limited by safety of transgene 
delivery strategies 
51 52   
Small Molecules and Viral Delivery of TFs 
(Human) 
~355.45 ~ 500 Limited by safety of transgene 
delivery strategies 
58 59    
Small Molecules Only (Human) 21 21 Promising. Further investigation 
of safety is required. 
57   
 
 In Table 1, it is clear that human cells are more difficult to convert at high efficiencies than 
mouse cells. This can be seen by comparison of the studies done on conversion by viral delivery of TFs to 
mouse and human cells. This is important because for clinical applications, it is necessary to induce 
human cells. Although non-viral methods have higher potential to be safe in clinical applications, their 
efficiencies are already low in studies using mouse cells. It is likely that non-viral TF methods would be 
even less effective in human cell conversion, limiting their clinical applicability. Non-viral TF 
transdifferentiation efficiency was increased by the additional use of electroporation and TES. The group 
who did this study also showed that PBAE nanoparticles complexed with BAM TF expressing plasmids 
could be transfected into mouse dermal fibroblasts through intradermal injection followed by applying 
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TES-generated electrical stimulation through electrocardiogram patches. This produced skin tissue with 
5.86% Tuj1+ cells 50. This showed some potential for development of a strategy for non-viral in vivo 
neuronal transdifferentiation for therapeutic applications, however the strategy seems fairly complex 
which could limit its potential. Therefore, a point of future study should be in continuing to develop 
strategies for making non-viral TF methods more efficient.  
 MicroRNA provides an additional way to influence gene regulation, and when used along with 
TFs can achieve improved conversion efficiency of human cells. However, it will still be advantageous to 
develop efficient non-viral methods for safe in vitro and in vivo delivery of microRNAs and TFs.  
Finally, small molecules appear to provide extreme enhancement in conversion efficiency. 
Although knowing that neurons are postmitoctic, it is surprising to see that conversion efficiencies could 
be far over 100%. These values were reported as the percentage of Tuj1+ cells in relation to the initial 
number of plated cells, as is common58. These values indicate that their methods must accommodate a 
large increase in cell number during conversion, presumably before neuronal conversion is complete. It is 
worth noting that these high conversion efficiencies were achieved when small molecules were used 
along with virally delivered TFs, which limits clinical applicability due to the safety concerns associated 
with the use of viruses. Small molecules have also been used alone to induce neuronal cells with a 
conversion efficiency surpassing those achieved by viral delivery of TFs58. This is very promising 
because such a method eliminates the need to design efficient transgene delivery systems and eliminates 
the safety concern of integrating transgenes. This method could potentially be used for clinical 
applications such as cell replacement therapy of neurological disorders. However, it still needs to be 





1.4. Non-viral Gene Delivery for Transdifferentiation 
 
 Some of the methods for inducing transdifferentiation, described previously, require the delivery 
of nucleic acids to the start cells in order to initiate their conversion. For example, TF mediated 
transdifferentiation requires the delivery of plasmid DNA containing TF-encoding genes. Because nucleic 
acids are highly charged, they cannot penetrate the hydrophobic core of a cell membrane. There has been 
plenty of research done on gene delivery systems for medical applications including gene therapy, 
vaccines, and controlling cell fate60-62 63. Most research uses viral gene carriers because their intrinsic 
ability to transfect cells is very efficient. However, there are safety concerns limiting the use of viral 
vectors in clinical practice, such as genotoxic integration of viral payloads and immunogenicity, making 
non-viral gene delivery systems preferable. However, non-viral vectors often have lower transfection 
efficiency and cause lower transdifferentiation efficiency, and therefore methodologies need to be 
improved. 
Retroviral and lentiviral vectors have been used extensively in research using TF induced 
transdifferentiation. They each have characteristics that can be useful depending on how one wishes the 
delivered genes to be incorporated and expressed in the cell. Both retrovirus and lentivirus are capable of 
transducing dividing cells and integrating transgenes into the host cell’s genome which provides a 
permanent genetic modification and the possibility of perpetual transgene expression63. However, this 
integration also has the potential to cause complications such as oncogene activation or tumor-suppressor 
gene inactivation, causing cancer. Lentiviral vectors can also transduce non-dividing cells, which makes 
them applicable to more cell types than standard retroviral vectors and most non-viral vectors, and they 
can be used to enable transient gene expression. In addition to the risk of tumorigenicity, viral vectors 
also have greater risk of causing immunogenic problems. Due to these concerns, there has been a focus on 
finding non-viral alternatives for gene delivery systems that could be lower risk for clinical applications. 
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1.4.1. Methods of Non-viral Delivery 
 
Nonviral transfection has been approached in many different ways including both physical 
methods (e.g. electroporation), biochemical methods (e.g. calcium phosphate co-precipitate, lipoplex and 
polyplex mediated gene delivery), and physical-biochemical hybrid methods (e.g. nucleofection and 
magnetofection). Although only a few non-viral gene delivery methods have been used in research on 
transdifferentiation, there are lot of new developing non-viral systems used in studies for other types of 
cell conversion (differentiation and reprogramming) and for other medical applications including gene 
therapy and vaccines. These methods could also potentially be used for inducing transdifferentiation. The 
examples of non-viral gene delivery systems described here are ones that have already been used in 
studies on cell conversion. 
 
1.4.1.1. Electroporation and Nucleofection 
 
A very common physical method, which has even been used in neuronal transdifferentiation, is 
electroporation50. Electroporation allows DNA to enter cells by disrupting the cell membrane and making 
it more penetrable to the highly charged nucleic acids. This is achieved by applying an electrostatic field 
across a cell and DNA suspension.  As a result, pores are formed in the cell’s membrane through which 
the DNA can travel to the inside of the cell. Electroporation can be used in vitro and in vivo and can 
transfect cells efficiently compared to other non-viral methods. However, it can also cause cell death 
making it less desirable in clinical applications. Nucleofection is a technique that uses electroporation 
along with cell-type specific reagents that enable nucleic acids to travel directly into the nucleus during 
electroporation. This non-viral technology is special for its ability to transfect non-dividing cells at high 





Many other systems of non-viral gene delivery make use of nanoparticles. These are often 
classified as biochemical methods. Nanoparticles can be loaded with DNA in various ways and are an 
ideal size to enter cells by endocytosis64, 65. For example, mesoporous silica nanoparticles have high 
loading capacity due to their highly porous structure, tunable charge, and low cytotoxicity which make 
them useful for gene delivery66. DNA can be electrostatically adsorbed to the interior walls of positively 
charged mesoporous silica nanoparticles and then delivered to cells. This technology has been used to 
differentiate iPSCs to definitive-lineage cells67. Another nanoparticle gene delivery system is calcium 
phosphate co-precipitation. In this system, DNA is mixed with calcium chloride in a saline/phosphate 
solution to generate calcium-phosphate-DNA co-precipitate in the form of small particles. These particles 
bind to the cell wall due to the calcium phosphate and enter cells through endocytosis. This was used in 
the first artificially induced transdifferentiation when embryonic mouse fibroblasts were converted to 
myoblasts with delivery of MyoD31. Calcium-phosphate co-precipitate particles can also help improve 
viral transfection by increasing the density of viral carriers that coat the cell surface followed by their 
entry into cells by endocytosis68.  
A nanoparticle method that combines both biochemical and physical influence to achieve gene 
delivery is magnetofection. DNA is first adsorbed onto magnetic nanoparticles made of biodegradable 
iron oxide, which are then added to cell culture medium and forced to approach cells using a magnetic 
field. The magnetic particles can form complexes with bare nucleic acids or form complexes with nucleic 
acids which are prepackaged in protective viral or non-viral carriers. Magnetofection promotes cellular 
uptake of DNA by forcing the entire dose towards the cells so that all cells come in contact with a large 
number of DNA complexes. Magnetofection has been used to non-virally reprogram mouse fibroblasts 
into iPSCs69. It has also been shown to have potential in aiding control of in vivo transfection by confining 
gene delivery to an area defined by the applied magnetic field70. 
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Recently, nanoparticle systems have been used to mediate gene delivery using peptide-modified 
dendrimer-entrapped gold nanoparticles71. Nanoparticle systems have also been applied to deliver TFs as 
proteins rather than genes. For example, this has been done using cationic bolaamphiphile particles and 
chitosan nanoparticles72, 73. Functionalized nanoparticles are not only being used as delivery vehicles, but 
also tools which themselves can promote cell differentiation74, 75.  
These nanoparticle systems have all been applied to some extent to induce either differentiation, 
reprogramming or transdifferentiation, although they have been primarily studied in the context of other 
clinical applications.  
 
1.4.1.3. Lipoplexes and Polyplexes 
 
 More common methods of non-viral gene delivery are the use of lipoplexes and polyplexes. 
These are complexes formed through the electrostatic interaction between DNA and cationic lipids or 
polymers, respectively. These synthetic vectors have been widely considered as promising alternatives to 
viral vectors for their improved safety, greater flexibility and easier manufacturability76. Many efforts 
have gone into the optimization of these systems to advance the clinical applicability of non-viral gene 
delivery. This is especially true for polyplex systems which have characteristics important for in vivo gene 
delivery, such as extracellular stability and targeted release 76, 77. 
Lipofection, the use of lipoplexes to transfect cells, was first reported in 198778. Lipopelxes form 
into heterogeneous populations of structures. These include more dense structures with DNA being 
surrounded by lipid as well as large structures with DNA outside of lipid structures or holding multiple 
lipid structures together79. These complexes enter cells through endocytosis and can be designed to 
promote endosomal escape to release DNA into cytoplasm. The cationic lipids can be categorized based 
on their structure into (1) monovalent aliphatic lipids with single amine functionality in their head group, 
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(2) multivalent aliphatic lipids with several amine functionalities in their head group, or (3) cationic 
cholesterol derivatives80. The addition of neutral lipids, such as dioleoylphosphatidylethanolamine 
(DOPE), dioleoylphosphatidylcholine (DOPC) and cholesterol, to the complexes can improve transfection 
efficiency. This is thought to be because they help destabilize lipid bilayers which promotes endosomal 
escape79. There are many commercially available cationic lipid transfection reagents including Cellfectin, 
Lipofectamine, and Lipofectin. Choosing which reagent to use will depend on the cell type and culture 
conditions used. Lipoplex systems often show cytotoxicity due to accumulation of positive charge inside 
cells 81.  
Polyplexes have received lots of attention due to their promising tunable properties76, 77. Linear, 
branched, or dendritic polymers can be used. DNA-binding groups can be incorporated into the polymer 
backbone, pendant groups or grafted molecules. They can also be designed with tunable biodegradability 
which helps with DNA release and reduces cytotoxicity76, 82. Polyethylenimine (PEI) was one of the first 
polymers used for effective gene delivery in 1995 83. PEI can be targeted to specific cell types by the 
conjunction of specific ligands and can aid endosomal escape through the proton-sponge effect 76, 84. 
Poly(amido amine) (PAA) dendrimers have also been used for polyplex gene delivery. These dendrimers 
are highly soluble and their size and surface charge can be precisely controlled. They have surface amine 
groups that can be highly functionalized to control surface charge. These polymers are also thought to 
elicit the proton sponge effect. Poly(lactide-co-glycolide) (PLGA) has also been used for gene delivery 
and has unique characteristics for controlled release, however its transfection efficiency suffers from its 
slow release of DNA. Finally, chitosan has been popular due to its excellent biocompatibility and 
biodegradability85. Chitosan has low toxicity and low immunogenicity, however it is insoluble at 
physiological pH. The polymers described have certain beneficial characteristics and show great potential 
for optimization and modification due to their tunability and functionalizability. 
There are still significant challenges to face in designing the ideal polymer gene delivery system. 
The primary obstacle is their low transfection efficiency, which is much lower than that of viral gene 
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delivery. Current polyplex systems tend to lack the necessary functionality to cross at least one of the 
many barriers encountered during gene delivery. These barriers can include gene packaging, serum 
stability, cell-specific targeting, endolysosomal escape, transport through cytoplasm, nuclear localization, 
and unpackaging76. Specifically, it can be a challenge to design polymers that can balance complex 
stability and protection of DNA during the delivery stage with efficient release of DNA inside the cell 82. 
Another challenge is to decrease their cytotoxicity. Cytotoxicity can occur due to accumulation of 
positive charge inside cells. As a result, there has been a focus on developing polyplexes that are 
hydrolytically degradable such as poly(β-amino ester)s (PBAEs). Their degradation both decreases 
cytotoxicity and is thought to improve the unpacking of DNA82. PBAEs have been used in non-viral 
neuronal transdifferentiation 50. However, they are not hydrolytically stable in the extracellular 
environment making them worse at protecting the DNA during transportation. PAAs are much more 
hydrolytically stable allowing them to successfully transport DNA to cells, however their hydrolytic 
degradation is very slow and does not contribute to the unpacking of DNA inside cells. One research 
group had the idea to use poly(amido amine)s with repeating disulfide linkages (SS-PAAs) which allowed 
the polymer to be hydrolytically stable, but also quickly degradable by reduction of the disulfide 
linkages82. By allowing degradation of the polymer to depend on reduction, the idea was to have the 
vectors selectively degrade inside cells where there are high concentrations of reductases, such as 
glutathione and thioredoxin reductase, capable of breaking the disulfide linkages. These polymers did 
show increased transfection efficiency and lower cytotoxicity compared to PEI controls82. 
Several SS-PAAs were designed with different primary amine monomers, which had previously 
appeared to be favorable in gene delivery research (Figure 1). The 4-amino-1-butanol (ABOL) side 
groups showed good transfection efficiency and cell viability compared to the other SS-PAAs. This 





Figure 1 Bioreducible poly(amido amine)s with repetitive disulfide linkages82.  
Reprinted with permission from Lin, C.;  Zhong, Z.;  Lok, M. C.;  Jiang, X.;  Hennink, W. E.;  Feijen, J.; Engbersen, J. F., Novel 
bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjug Chem 2007, 18 (1), 138-45. Copyright 2007 
American Chemical Society. 
 
 
1.5. Topography-enhanced Transfection Efficiency 
 
For successful transfection, genes must reach the nucleus of a cell where they can be expressed, 
and translated into proteins. Many barriers are encountered as the DNA complexes travel to a cell’s 
surface, pass into a cell, travel through the cytoplasm, and enter the nucleus86. Each barrier reduces the 
overall efficiency of transfection. Since viruses have evolved to cross these barriers efficiently, viral 
vectors are much more efficient at transfecting cells than non-viral vectors. Low efficiency is the main 
limitation of the use of non-viral vectors compared to their viral counterparts due to imperfect 
performance at overcoming these barriers, which is not always well understood, and the compounding 
effect this can have on overall transfection efficiency. Development of ideal non-viral DNA carriers has 
been the focus of research efforts in improving efficient non-viral transfection systems, however substrate 
influences can also have significant effects on cells and their transfection efficiency86.   
Non-viral vectors enter cells by endocytosis. Macropinocytosis and clathrin- and caveolae-
mediated endocytosis are the most studied in the context of non-viral carriers and can occur to varying 
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degrees depending on cell type and DNA complex characteristics86. Substrate characteristics can 
influence endocytosis through various mechanisms. The nano- and micro- topography of a substrate is 
known to affect a cell’s rate of cell proliferation, cell differentiation, protein expression, cell spreading, 
and focal adhesion turnover. These cell functions can then affect the process of endocytosis. Investigating 
the influence of nano- and micro-topographies on the internalization of non-viral vectors may be a 
promising route for improving transfection efficiency. 
Previous research studying the effects of substrate nano- and micro-topography on cellular 
endocytosis has shown that grating topographies of micron-width on fused silica substrates could cause 
an increase in phagocytosis by murine macrophages with increasing grating depth (ranging from 44 to 
282nm)87. It has also been observed that human fibroblasts cultured on poly(methyl methacrylate) 
(PMMA) substrates with nano-pillars (160nm height, 100nm diameter, and 230nm pitch) would attempt 
to internalize the pillars through clathrin-mediated endocytosis88. Human osteoblasts have also been seen 
to attempt internalization of fixed titanium micro-pillars (5µm height, 5µm diameter, and 5µm pitch) 
through caveolae-mediated phagocytosis89. Electrospun PMMA fibrous scaffolds can modulate the 
mechanical properties and morphologies of human osteosarcoma cells which in turn modulate uptake of 
polystyrene nanoparticles90.  
Substrate topography has also been used to influence endocytosis to enhance the efficiency of 
non-viral transfection. One study screened a library of 160 different micro-scale pit geometries on 
polydimethylsiloxane (PDMS) substrates and found that the efficiency of Lipofectamine-mediated green 
fluorescent protein (GFP)  transfection of human dermal fibroblasts could be improved 25% with pits of 
4µm width and 1µm spacing compared to unpatterned substrates16. Another study compared nano- and 
micro-topographical effects as well as the effects of isolated pillar topographies and continuous grating 
topographies on endocytosis and transfection efficiency17. One of the findings was that a PMMA surface 
patterned with 200nm pillars could increase the efficiency of GFP delivered to hMSCs by Lipofectamine-
mediated transfection in comparison to unpatterned controls.  
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1.6. Topography-enhanced/induced Differentiation and Transdifferentiation 
 
 Substrate topography has also been shown to have significant direct influence on cell conversions 
including differentiation and transdifferentiation91. Topography can enhance the differentiation of 
neuronal stem cells (NSCs), neuronal progenitor cells (NPCs), ESCs, and iPSCs to neurons as well as the 
neuronal transdifferentiation of fibroblasts and MSCs 18, 19, 92-98. One study screened various topographies 
with different isotropic and anisotropic geometries and both nano- and micro-dimensions on PDMS 
substrates for their influence on mNCP differentiation 92. Anisotropic nano- and micro-gratings as well as 
isotropic micro-pillars promoted neuronal differentiation while isotropic micro-pillars and holes promoted 
glial differentiation. Differentiation of mNPCs on PDMS substrates with gratings of 2µm width, 2µm 
spacing, and varying depth has shown that neurite elongation, alignment, and neuronal differentiation all 
increase with grating depth93. Electrospun polyphenylene sulfone (PPSU) nanofibers have been shown to 
be able to enhance neuronal differentiation of NSCs compared to 2D substrates as well as increase the 
activity of the neurons and control the direction of neural signals99. Screening of various micro- and nano-
scale gratings, pillars, wells and hierarchical topographies on PMMA substrates showed that anisotropic 
patterns like gratings promoted neuronal differentiation of hESCs, and isotropic patterns such as pillars 
and wells promoted glial differentiation of hESCs95. Another study looked at differentiation of iPSCs into 
neuronal cells on electrospun fibrous substrates made from tyrosine-derived polycarbonate compared to 
2D substrates of the same material made by spin coating96. The cells were infected with lentivirus to 
deliver the single transcription factor NeuroD1 before being seeded onto fibrous substrates. It was 
reported that the 3D fibrous substrates could guide maturation, electrical activity, and cell type purity in 
vitro. iN cells on 3D fibrous scaffolds around 100µm in size (with fibers around 3µm thick) were injected 
into ex vivo brain tissue and showed improved neurite outgrowth, cell survival, and electrical activity 
compared to cells injected without microscale substrates. Finally, when injected in vivo to mouse 
striatum, the fibrous scaffolds improved cell survival and engraftment.  
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Neuronal transdifferentiation of both hMSCs and MEFs has been enhanced by topographical 
influence. Additionally, hMSCs have been converted to neuronal-like cells by topography influence 
alone18, 19, 97, 98. hMSCs cultured on PDMS substrates with 350nm gratings acquired aligned and elongated 
cytoskeletons and nuclei, and showed up-regulation of neuronal markers18. When biochemical cues were 
additionally used to influence hMSCs towards neuronal lineage, the up-regulation of neuronal markers 
was further enhanced, however the nano-gratings were shown to have the largest impact on the 
transdifferentiation. Another study reported findings suggesting that nano-gratings induce this differential 
gene expression in hMSCs because hMSCs sense and transduce topographical signals through focal 
adhesions and actomyosin cytoskeleton contractility19. The influence of nano-topography on 
transdifferentiation of mouse embryonic fibroblasts to induced neurons by lentiviral delivery of BAM 
transcriptions factors has also been investigated 97. The topographies studied included micro-posts (1µm 
diameter with 4µm spacing and 5µm depth, and 4µm diameter with 1µm spacing and 5µm depth) and 
micro-gratings (5µm width, spacing and depth) on polystyrene (PS) substrates. Final iN purity, 
conversion efficiency, and gene expression were improved with the micro-gratings, and neurite branching 
was increased on the micro-posts, but decreased with micro-gratings while neurite length was increased 
with both gratings and posts. Substrate topographies have also been shown to be beneficial in producing 
dopaminergic neurons by transdifferentiation98. 
 
1.7. PDMS Used for Patternable Substrates 
 
Polydimethylsiloxane (PDMS) is a very commonly used polymeric organosilicon compound. It 
has been used extensively in microfluidics and soft lithography as well as biomedical applications such as 
drug delivery vehicles, blood-contacting biomaterials and microfluidics involving mammalian cell 
culture100, 101. This material is also often used to fabricate substrates for studying topographical or other 
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mechanical influence on cells. PDMS has ideal characteristics for cell culture including nontoxicity, 
biocompatibility, transparency, thermal stability and durability100, 102. Also the material can be patterned 
with micro- or nano-topographies by soft lithography and these topographies can be fabricated with good 
repeatability 92, 103, 104.  
The structure of PDMS is shown in Figure 2. PDMS is made using a base (which is 
predominantly dimethylvinyl-terminated dimethylsiloxane), a curing agent (mostly comprised of 
dimethylhydrogen siloxane), and a metal-centred catalyst to promote crosslinking105. After curing, the 
surface of PDMS is hydrophobic which does not facilitate cell adhesion. Plasma oxidation can be used to 
make the PDMS surface more hydrophilic by adding silanol (SiOH) groups to the surface106, 107. The 
hydrophilicity achieved by plasma oxidation may decrease over time due to surface reorganization which 
can make PDMS poor at supporting cell cultures for long periods of time100. Longer cell culture on PDMS 
can be promoted by coating with extracellular matrix (ECM) proteins such as fibronectin, laminin, and 
collagen to support prolonged cell adhesion. 
 
 
Figure 2 Molecular structure of PDMS. n indicates the repeating monomer.  
 
 Due to its tunable stiffness, elasticity, patternability, and compatibility with cell culture, PDMS 
has been used extensively to investigate the influences of substrate physical properties on cell behavior.  
For example, stiff and soft PDMS substrates were made to have a 10-fold difference in Young’s modulus 
by using a 10:1 and 50:1 ratio of base to curing agent108. With these substrates, it was shown that mouse 
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hippocampal neurons cultured on stiff substrates had enhanced neuronal network activity. Another study 
used PDMS as a flexible cell culture substrate in a stretching device and showed cyclic stretching of soft 
substrates induces spreading and growth of PMEFs109. Finally, the patternability of PDMS has allowed 
investigation of the influence of micro- and nano-topographical substrates on cell behaviors including 
studies mentioned earlier looking at topographical influence on non-viral transfectability of cells and cell 
conversion16, 18, 19, 110 17. 
 
1.8. Project Motivation, Hypotheses, and Thesis Outline 
 
Having a source of neuronal cells suitable for medical applications would be of great value. Cells 
fabricated by differentiation of ESCs or reprogramming followed by differentiation of iPSCs have their 
limitations, but have provided insight and inspired further study of other possible cell conversion 
processes. Transdifferentiation is a promising solution to many of the limitations associated with the use 
of ESCs and iPSCs, however most successes in the study of transdifferentiation have depended on the 
efficiency of viral transfection which is a hindrance to its clinical translatability. Non-viral neuronal 
transdifferentiation of mouse embryonic fibroblasts has been achieved with delivery of BAM neuronal 
lineage-specific transcription factors, but with low conversion efficiencies15, 50. In order to apply neuronal 
transdifferentiation to human cells and to make the process of neuronal induction relevant for use, 
neuronal transdifferentiation efficiency must be improved.  
Interestingly, influence from nano- and micro-topography of cell substrates has been shown to 
enhance non-viral transfection and non-viral neuronal transdifferentiation in certain scenarios. The studies 
that relate to topographical effects on non-viral transfection which were most impactful in motivation of 
this thesis project showed that (1) PMMA substrates patterned with nano-pillars could increase the 
efficiency of non-viral Lipofectamine-mediated transfection of hMSCs compared to unpatterned 
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substrates17 and (2) PDMS substrates patterned with micro-pits could increase the efficiency of non-viral 
Lipofectamine-mediated transfection of human dermal fibroblasts compared to unpatterned substrates16. 
Furthermore, the studies demonstrating topographical effects on non-viral transdifferentiation which were 
most impactful in the motivation of this project showed that (1) hMSCs cultured on PDMS substrates 
with nano-gratings showed up-regulation of neuronal markers18, 19 and (2) transdifferentiation of mouse 
embryonic fibroblasts could be enhanced by topographies on PDMS substrates including micro-pillars, 
micro-holes, and micro-gratings20. In this study, we screened an array of nano- and micro-scale patterns 
with a wide variety of geometries on PDMS substrates for the effect that they have on non-viral 
transfection and non-viral neuronal transdifferentiation of hMSCs. 
Our hypotheses are: 
1. Nano- or micro-topographical PDMS substrates would be able to increase non-viral transfection 
efficiency of hMSCs. 
2. Nano- or micro-topographical PDMS substrates would be able to enhance non-viral neuronal 
transdifferentiation of hMSCs. 
In the next chapters of this thesis, the methods, results, and discussion of the two main 
components of this project will be presented, followed by a conclusion and recommendations for future 
work. Chapter 2 presents our work on topographical influence on non-viral transfection of hMSCs. 
Chapter 3 studies the topographical effects on non-viral neuronal transdifferentiation of hMSCs. Finally, 










This chapter covers the methods and results of experiments aiming to address the hypothesis that 
nano- or micro-topographies can influence the efficiency of non-viral transfection of hMSCs. For these 
investigations, Lipofectamine 2000 was used to transfect hMSCs with an EGFP-expressing plasmid on 
topographically-patterned PDMS substrates. Lipofectamine was chosen as the non-viral transfection 
reagent for these studies since it is commonly used and commercially available. The EGFP-encoding 
plasmid was used so that transfection efficiency could be easily quantified using fluorescence imaging. 
PDMS MultiARChitecture (MARC) chip substrates were used to screen an array of micro- and nano-
topographies (including gratings, lenses, pillars, wells, and hierarchical structures). MARC chip 
substrates increased screening throughput and decreased variability by enabling screening of all 




2.2.1. PDMS MARC Chip and Unpatterned Chamber Substrate Fabrication 
 
The original MARC chip master mold was prepared previously 92, 95, 103. This master mold was 
composed of polycarbonate (PC) patterned areas arranged onto a silicon substrate and fused together into 
28 
 
a single layer with PDMS which formed unpatterned areas which framed the patterned PC areas (Figure 
3). This was used to make a PDMS mold (Figure 4A), which had mirror image replicas of the 
topographies.  The PDMS mold was then used to make the PDMS MARC chip substrates by soft 
lithography (Figure 4A). To do this, the PDMS mold was silanized by placing the mold into a vacuum 
chamber with 25µl of Trichloro(1H,1H,2H,2H-perfluorooctyl)silane (silane, Millipore Sigma) which was 
vacuum pumped for 30 minutes to create a low pressure environment that would cause the silane to 
vaporize. The vacuum was then turned off and the mold was left exposed to the silane vapor overnight. 
PDMS (Sylgard 184, Corning) was mixed at a 10:1 mass ratio of base to curing agent and poured onto the 
mold. The liquid PDMS was degassed for 15 minutes to remove large air bubbles and for an additional 30 
minutes with a coverslip placed on top to encourage the complete filling of mold features. Afterwards, the 
filled mold was placed in an oven at 60°C overnight (around 12 hours) for PDMS curing. The newly 
formed PDMS MARC chip substrate was then peeled off the mold and placed back into the oven at 60°C 
for up to seven days in order to reduce the risk of having un-crosslinked oligomers in the PDMS 
substrates which could be toxic to cells during longer-term cultures. Soft lithography was repeated to 
make multiple MARC chip substrates. As an additional precaution, the first five MARC chips made from 
the mold after silanization were not used for cell culture experiments to reduce the risk of having residual 










Figure 3. Topographical patterns and layout of MARC chip substrates. (A) Schematic diagram showing the arrangement of 
topographical patterns on MARC chip master molds made of PC (pink), PDMS (yellow), and Si backing covered by a PC sheet 
(brown). The PC areas labeled UP are unpatterned control areas. (B) List of patterns on MARC chip master mold and replicated 
onto PDMS MARC chip substrates.  
 
 
Figure 4. PDMS MARC chip and unpatterned chamber substrates fabrication. (A) Fabrication of MARC chip substrates by 
soft lithography. (B) Fabrication of unpatterned chamber substrates. (1) PDMS (10:1 ratio of base to curing agent) is poured onto 
the master mold, degassed, and cured overnight. (2) PDMS Mold is silanized, PDMS (10:1 ratio of base to curing agent) is 
poured onto the PDMS mold, degassed, and cured overnight. (3) PDMS is cut with extra space around mold to create chamber 
walls. 
 
The MARC chips fit into the wells of a 6-well tissue culture plate, however, during fabrication 
these substrates were also made to have their own chamber walls (Figure 4A and Figure 5A). These 
helped to keep cells from falling off the MARC chip during cell seeding, and helped to reduce the 
consumption of reagents by limiting excess space around the cell culture surface area of interest. 
1. 250 nm lines, 250 nm space, 250 nm height 
2. 250 nm lines, 250 nm space, 110 nm height 
3. 460 nm lines, 70 nm space, 40 nm height 
4. 2 µm lines, 2 µm space, 2 µm height 
5. 1 µm lines, 2 µzam space, 120 nm height 
6. 2 µm lines, 1µm space, 80 nm height 
7. 250 nm lines on 2 µm lines (perpendicular) 
8. 250 nm lines on 2 µm lines (parallel)  
9. 250 nm pillars on 2 µm lines 
10. 1 µm diameter & pitch, 0.3 µm sag concave microlens 
11. 1 µm diameter & pitch, 0.3 µm sag convex microlens 
12. 1.8 µm diameter, 2 µm pitch, 0.7 µm sag concave microlens 
13. 1.8 µm diameter, 2 µm pitch, 0.7 µm sag convex microlens 
14. 2 µm pillars, 12 µm pitch, 2 µm height 
15. 1 µm holes, 6.5 µm pitch, 1 µm depth 




















Unpatterned PDMS control substrates with chamber walls (Figure 5B) were made similarly by 
pouring PDMS onto unpatterned PDMS molds followed by the same procedure (Figure 4B).  
 
        
Figure 5. PDMS MARC chip and unpatterned chamber substrates in 6-well tissue culture plates. (A) MARC chip chamber 
substrate. (B) Unpatterned chamber substrate. Arrows point out PDMS chamber walls. 
 
2.2.2. Sample Preparation for Scanning Electron Microscopy for Verification of Substrate 
Topographies 
 
In preparation for scanning electron microscopy (SEM) imaging, PDMS substrates were cut into 
sections to fit onto 0.5” aluminum stubs (Agar Scientific). PDMS samples were adhered to the stubs with 
double sided carbon tape (Electron Microscopy Sciences) and the edges were coated with silver 
conductive paste (Sigma Millipore) to make a conductive bridge to the top surface of the sample (Figure 
6). After at least 24 hours of letting the silver paste dry, the samples were gold coated with a Denton 
Vacuum Desk II sputter coater. Samples were put in a degasser, vacuum pumped for 30 minutes to create 
a low pressure environment, and left overnight to help remove moisture from the samples the night before 




          
Figure 6. Mounted section of MARC chip substrate prepared for SEM imaging. (A) Angled view. (B) Top view. 
 
2.2.3. Cell Culture and Substrate Sterilization 
 
Human MSCs (Lonza) were thawed in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) 
with 10% MSC qualified fetal bovine serum (Gibco) and expanded in MesenPRO RS medium (Gibco), a 
reduced serum (2%) medium formulated to support the growth of hMSCs, supplemented with 2 mM L-
glutamine (Gibco) following Gibco’s protocol. They were seeded for experiments between passages 5 to 
7. Prior to seeding, PDMS substrates were plasma treated (Zepto, Diener Electronic), sterilized by sitting 
submerged in 70% ethanol for 30 minutes followed by UV irradiation for 20 minutes, and briefly rinsed 
with sterile phosphate buffered saline (PBS, Fisher BioReagents). Glass substrates were flame sterilized 
before cell seeding. 
 
2.2.4. EGFP Plasmid Amplification  
 
EGFP plasmid was shipped as purified plasmid from the Mechanobiology Institute, National 
University of Singapore, and tested upon arrival by observing fluorescence in transfected fibroblasts. For 
plasmid amplifications, 5 µl of plasmid DNA was combined with 50 µl of NEB 5-alpha Competent E. 




University of Waterloo, and then incubated on ice for 30 minutes. The cells were then heat shocked in a 
water bath at 42 °C for 45 seconds to transform the bacterial cells and then put back on ice. Five hundred 
microliters of SOC media (Sigma) was then added to the cells which were then incubated with shaking at 
37 °C and 275 rpm for 1 hour. After incubation, 50 µl of the cell suspension was spread onto an agar plate 
containing kanamycin (Bio Basic). The plate was incubated at 37 °C overnight. The next day cells from 
an isolated colony on the agar plate were added to 25 ml of lysogeny broth (LB) with kanamycin and 
incubated in a flask on a shaker overnight at 37 °C and 275 rpm. The plasmid was purified using a 
QIAGEN Plasmid Midi Kit. The final purified plasmid concentration was measured with a NanoDrop 
ND-1000 Spectrophotometer. 
 
2.2.5. Lipofectamine-mediated EGFP Transfection, Sample Staining, Fluorescence Imaging, and 
Transfection Efficiency Quantification  
 
All Lipofectamine-mediated transfections were carried out with Lipofectamine 2000 (Invitrogen) 
by following Invitrogen’s recommended protocol with a 36 hour transfection incubation time. Unless 
otherwise specified, samples were then prepared for fluorescence imaging. First, media was removed 
from the samples. The cells were washed once with PBS, and then fixed with pH adjusted 4% 
paraformaldehyde (PFA, Millipore Sigma) in PBS for 15 minutes. After fixing, samples were washed 
again with PBS and then permeabilized with 0.1% Triton X-100 (Sigma Millipore) in PBS for 15 
minutes. After permeabilization, samples were washed once more with PBS, after which the cells were 
stained with either 1:2500 4′,6-diamidino-2-phenylindole (DAPI, Sigma Millipore) in PBS or with both 
1:2500 DAPI and 1:750 Alexa Fluor 546 Phalloidin (Invitrogen) in PBS at 4 °C overnight. After staining, 
samples were washed again with PBS and then mounted onto glass coverslips with Fluoromount 
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(Invitrogen) for imaging. Imaging was done using epi-fluorescence microscopy (Zeiss Axio 
Observer.Z1).  
 To quantify transfection efficiency from the fluorescence images, the total number of cells in the 
images were counted using ImageJ software (NIH) and the number of EGFP expressing cells were 
counted by visual inspection. The transfection efficiency was quantified as the percentage of total cells 
imaged that expressed EGFP (Equation 2.1). A minimum of 100 cells were considered for each sample 
unless otherwise specified.  
 
 𝑇𝑟𝑎𝑛𝑠𝑓𝑒𝑐𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐸𝐺𝐹𝑃 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐶𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝑒𝑙𝑙𝑠
× 100% (2.1) 
 
 
2.2.6. Determining Optimum Lipofectamine Concentration for hMSC Transfection 
 
Following Invitrogen’s recommendation, a few different DNA (µg) to Lipofectamine (µl) ratios 
were tested for our application before proceeding to our topography experiments. Ratios of 1:0.4, 1:2, and 
1:3 were tested. The amount of EGFP-expressing plasmid DNA delivered to cells was held constant at 
0.25 µg/cm2. Negative controls did not receive any plasmid DNA. These tests were conducted on 
unpatterned glass substrates. Samples transfected with a 1:0.4 ratio were also made on unpatterned PDMS 
substrates to control for the effect of substrate material on Lipofectamine-mediated transfection. Human 
MSCs were seeded at a density of 5000 cells/cm2. Thirty-six hours after seeding, cells were transfected 





2.2.7. Determining Appropriate Seeding Density for Transfection studies on PDMS Substrates 
 
To determine the seeding density that could be used to achieve 50-90% confluence of hMSCs on 
PDMS substrates, as is recommended by Invitrogen for optimal Lipofectamine-mediated transfections, 
hMSCs were seeded at 2000, 5000, and 8000 cells/cm2 on PDMS substrates.  Thirty-six hours after 
seeding, cells were fixed and stained with DAPI and Alexa Fluor 546 Phalloidin (as described in section 
2.2.5). Cells were imaged with fluorescence microscopy to observe the resulting confluence. Samples 
seeded at 5000 and 8000 cells/cm2 were found to give better confluence and so were transfected with 
EGFP-expressing plasmid (as previously described in section 2.2.5) with a DNA (µg) to Lipofectamine 
(µl) ratio of 1:0.4, in order to determine if this change in seeding density would affect transfection 
efficiency. Cells were fixed and stained with DAPI and Alexa Fluor 546 Phalloidin for fluorescence 
microscopy and transfection efficiency quantification as previously described (section 2.2.5). 
 
2.2.8. Screening Topography Influence on Lipofectamine-mediated Transfection 
 
 To screen for influence of topographies on transfection efficiency, hMSCs were seeded at 8000 
cells/cm2 onto PDMS MARC chip substrates, transfected with EGFP-expressing plasmid using a 1:0.4 
plasmid (µg) to Lipofectamine (µl) ratio, and stained with DAPI and Alexa Fluor 546 Phalloidin with 
methods described (section 2.2.5). Two by two tiled 10X magnification fluorescence images were taken 
of each patterned area of the MARC chip to capture the entirety of each area (Figure 7). Transfection 
efficiency for each pattern was calculated as the total number of EGFP positive cells combined from each 
area corresponding to the pattern divided by the total number of cells imaged on those areas. Any image 
with zero cells was not included in the analysis. Also, if the total number of cells combined from all the 
areas corresponding to a pattern on one MARC chip sample was less than 50, that pattern on that MARC 
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chip was not included in the presented results. Results from each MARC chip were normalized to the 








Figure 7. Quantification of transfection efficiency for patterns on MARC chip samples. Transfection efficiency for each 
topography was measured by taking fluorescence images of each area corresponding to the pattern and counting the percentage of 
cells expressing EGFP. EGFP-positive and total cell counts from all images corresponding to a pattern were pooled together to 
calculate transfection efficiency.  
 
2.2.9. Investigating Cell Density and Cell Area on MARC Chip Topographies 
 
Both cell density and average cell area were quantified for each topography of the MARC chip 
from fluorescent images taken during the transfection study (section 2.2.8). Cell density was quantified by 
dividing the cell count by the area of the image. These values were normalized by dividing by the average 
cell density of the unpatterned areas of the same MARC chip. Cell densities and transfection efficiencies 
were calculated from the same images. Average cell area was quantified by obtaining the fraction of the 
area containing cells using ImageJ software, multiplying by the total image area, and dividing by the cell 







𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐸𝐺𝐹𝑃 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐶𝑒𝑙𝑙𝑠 
(𝑓𝑟𝑜𝑚 𝑖𝑚𝑎𝑔𝑒 𝐴 𝑎𝑛𝑑 𝐵 𝑐𝑜𝑚𝑏𝑖𝑛𝑒𝑑)
𝑇𝑜𝑡𝑎𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝑒𝑙𝑙𝑠 




2.2.10. Statistical Analysis 
 
Statistical analyses were performed using a one-way analysis of variance (ANOVA) test with 
Dunnett’s or Tukey’s multiple comparisons test or using an unpaired t-test using Prism (GraphPad). All 
values are presented with mean values ± standard deviation. Statistical tests were considered significant 





2.3.1. Scanning Electron Microscopy Verification of PDMS Substrate Topographies 
 
The presence of topographical patterns on PDMS MARC chip substrates was verified by SEM 
imaging (Figure 8). The images show that soft lithography was an effective method for patterning the 
substrates with both micro- and nano- topographies. Line spacing of 250 nm high nano-gratings (pattern 
1) were sometimes inconsistent (Figure 5 red arrow). This was likely due to the merging of multiple 








Figure 8. SEM images of topographical patterns on PDMS substrates. The red arrow on pattern 1 points out inconsistent 
spacing of 250 nm high nano-gratings. 







2 - 250 nm lines, 250 nm space, 110 nm height 
 
1 - 250 nm lines, 250 nm space, 250 nm height 
 
3 - 460 nm lines, 70 nm space, 40 nm height 
 
 
4 - 2 µm lines, 2 µm space, 2 µm height 
 
5 - 1 µm lines, 2 µm space, 120 nm height 
 























































2.3.2. Effect of Plasmid to Lipofectamine Ratio on hMSC Transfection Efficiency 
 
Fluorescence images of hMSCs on unpatterned glass substrates transfected with three different 
ratios of DNA (µg) to Lipofectamine (µl) showed that similar transfection efficiencies were achieved by 
transfections with a ratio of 1:0.4 as were achieved with higher ratios of Lipofectamine (Figure 9). 
Quantification of transfection efficiency confirmed these observations (Figure 10). Average transfection 
efficiencies of 6.9 ± 1.74%, 6.0 ± 0.44%, and 7.1 ± 1.33% resulted from using ratios of 1:3, 1:2, and 1:0.4 



























respectively. hMSCs seeded on unpatterned PDMS substrates transfected with a 1:0.4 ratio had 
transfection efficiency of 6.1% ± 0.91%, which showed that using a PDMS substrate did not affect 
performance of Lipofectamine-mediated transfection. Because no significant difference in transfection 
efficiency was observed between any of the samples, the lowest tested ratio of Lipofectamine (1:0.4) was 
used for all of the subsequent experiments to reduce risk of toxicity to cells as well as unnecessary 
consumption of the reagent. 
 
    
Figure 9. Fluorescence images of hMSCs transfected with varying ratios of DNA to Lipofectamine. The first three images 
from left to right represent the percentage of cells expressing EGFP (green) after transfection using 1:3, 1:2, and 1:0.4 ratios of 
DNA (µg) to Lipofectamine (µl). The image on the right shows non-transfected controls. Cells are stained with DAPI (blue). 
These samples were on unpatterned glass substrates. Scale bars are 100 µm. 
 
 
Figure 10. Quantification of transfection efficiency of hMSCs transfected with varying ratios of DNA to Lipofectamine. 
Transfection efficiency of hMSCs transfected by using 1:3, 1:2, and 1:0.4 ratios of plasmid (µg) to Lipofectamine (µl) on 
unpatterned glass substrates and using a 1:0.4 ratio on unpatterned PDMS substrates (n=3). 
1:3 1:2 1:0.4 Non-transfected 
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2.3.3. Effect of Seeding Density on Confluence of hMSCs on PDMS Substrates and Evenness of 
Seeding across PDMS MARC Chip Substrates 
 
In order to determine seeding density on PDMS substrates that would achieve 50-90 % cell 
confluency, recommended for Lipofectamine transfections, cells were seeded at 2000, 5000, and 8000 
cells/cm2. Based on fluorescence imaging 36 hours after seeding, a seeding density of 8000 cells/cm2 gave 
the best results on unpatterned PDMS substrates (Figure 11 A-C). Increasing seeding density from 5000 
to 8000 cells/cm2 did not have any effect on the efficiency of Lipofectamine-mediated transfection 
(Figure 11 D).  
 
     
 
Figure 11. Confluence and transfection efficiency after seeding hMSC at varying densities. Fluorescence microscopy images 
showing resulting confluence of hMSCs seeded on unpatterned PDMS substrates at (A) 2000, (B) 5000, and (C) 8000 cells/cm2. 
Cells are stained with Alexa Fluor 546 Phalloidin (red) and DAPI (blue). Scale bars are 100 µm. (D) Resulting transfection 
efficiency of cells seeded at 5000 and 8000 cells/cm2 on unpatterned PDMS substrates (n=2).  
2000 cells/cm2 5000 cells/cm2 8000 cells/cm2 




When cells were seeded onto a PDMS MARC chip at 5000 cells/cm2, only about 11% of the 
patterned areas had over 20% cell confluency. These areas were dispersed across the MARC chip. The 
other patterned areas only had cells close to their edges. This could have been due to variable effects that 
the topographies have on cell attachment. With a higher seeding density of 8000 cells/cm2, cells were 
more uniformly seeded across all topographical areas of the MARC chip at 36 hours after seeding. For 
this reason, in all subsequent experiments presented in this chapter, cells were seeded at 8000 cells/cm2. 
Figure 12 shows the confluence of cells, seeded at 8000 cells/cm2, on various patterns of the MARC chip 











Figure 12. Cell density on MARC chip patterns after seeding at 8000 cells/cm2. Fluorescence images of hMSCs on areas of 
PDMS MARC chip patterned with topographies (1 to 16) and on unpatterned area of MARC chip (UP), 72 hours after cells were 
seeded at 8000 cells/cm2. Cells are stained with Alexa Fluor 546 Phalloidin (red) and DAPI (blue). The arrow (bottom right) 
represents the direction of gratings. Scale bars are 500 µm. 
 
2.3.4. Effects of Topographies on Cell Density and Cell Area 
 
Quantification, from fluorescence images taken of hMSCs on MARC chip topographies after 
transfection, showed that none of the topographies caused statistically significant differences in final cell 
density compared to the unpatterned areas of the MARC chips (Figure 13 A). Quantification of average 
1 2 3 4 5 6 
7 8 9 10 11 12 
13 14 15 16 UP 
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cell area on the MARC chip showed that the hierarchical topography with 250 nm pillars on 2 µm 
gratings with 2 µm spacing and 2 µm height (pattern 9) caused a statistically significant decrease in 
average cell area compared to the unpatterned areas of the MARC chips with P ≤ 0.05  (Figure 13 B). It 
was notable that all of the topographies involving 2 µm wide gratings with 2 µm spacing and 2 µm height 
(patterns 4, 7, 8, and 9) caused a decrease in the mean cell area. This is likely related to the fact that cells 
aligned along the 2 µm grating topographies only extending along the grating axis and not extending in 
other directions, as can be seen in Figure 12.  
 
 
Figure 13 Normalized final cell density and average cell area on patterns of the MARC chip after transfection. (A) Final 
cell density values from each pattern of a MARC chip were normalized to the results of the unpatterned area of the same MARC 
chip. 2 ≤ n ≤ 7 is the number of MARC chips. (B) 4 ≤ n ≤ 8 is the number of patterned areas, on two different MARC chips, from 
which data was taken. * denotes statistical significance with p ≤ 0.05. The red lines indicate the levels of normalized final cell 
density and average cell area on unpatterned areas of MARC chips. 
 
2.3.5. Effects of Topographies on Efficiency of Lipofectamine-mediated Transfection 
 
 Screening of Lipofectamine-mediated EGFP transfection of hMSCs on PDMS MARC chip 
substrates did not show statistically significant changes in transfection efficiency caused by the 




highest positive or negative effect on transfection were selected for further study based on the trends seen 
in these results. The topographies selected were gratings with 250 nm width, spacing, and height (pattern 
# 1), gratings with 1 µm width, 2 µm spacing, and 120 nm height (pattern #5), concave lenses with 1 µm 
diameter and pitch, and 0.3 µm sag (pattern # 10), convex lenses with 1 µm diameter and pitch, and 0.3 
µm sag (pattern # 11), holes with 1 µm diameter, 6.5 µm pitch, and 1 µm depth (pattern #15), and pillars 
with 250 nm diameter, 400 nm pitch, and 250 nm height (pattern # 16). Figure 15 shows representative 
fluorescence microscopy images of transfected cells on these selected patterns.  
 The topography patterns selected due to their increase in transfection efficiency were 1, 5, 10, 15, 
and 16 (6 was not included because it is similar to pattern 5; pattern 6 was gratings of 2 µm width, 1µm 
spacing, 80 nm height). Pattern 11 was selected because of particular interest in its contrasting effects 
compared to pattern 10. Since the two patterns are inverse of each other (concave and convex micro-
lenses of the same dimensions), we would be interested to see if the direction of curvature would correlate 
to an effect on transfection efficiency. Interestingly, patterns 1, 5, and 10 which increased the mean 
transfection efficiency also showed decreased cell density compared to unpatterned controls (Figure 13 
A). 
     
Figure 14. Transfection efficiency achieved on patterned areas of MARC chip. Values are normalized to results from 
unpatterned areas of the same MARC chip sample (2 ≤ n ≤ 7). Red line indicates the level of transfection on unpatterned areas of 
MARC chips. The same data is represented in the bar graph (left) and dot plot where each dot represents an experiment replica 




















Figure 15. Representative fluorescence microscopy images of EGFP transfected cells on patterned areas of MARC chip 
for selected patterns. Numbers and labels identify the topographical patterns. Cells are stained with Alexa Fluor 546 Phalloidin 
(red) and DAPI (blue). Scale bars are 200 µm. 
 
2.3.6. Correlation of Transfection Efficiency with Cell Density and Cell Area 
 
Based on the observation that certain topographies with the strongest positive effect on 
transfection efficiency also have a negative effect on cell density (patterns 1, 5, 6, and 10) and that certain 
topographies with a negative effect on transfection efficiency also have a positive effect on cell density 
(patterns 11, 12, 13, and 14), we were interested to see how these two factors were correlated in our data. 
The scatter plot presented in Figure 16 shows the mean normalized transfection efficiency observed on 
each topography of the MARC chip versus the mean normalized final cell density of each topography. 
5 - gratings of 1 µm width, 2 µm 
spacing, and 120 nm height 
  
10 - concave lenses of 1 µm 
diameter and pitch, and 0.3 µm sag 
1 - gratings of 250 nm width, 
spacing, and height 
  
11 - convex lenses of 1 µm diameter 
and pitch, and 0.3 µm sag 
15 - holes of 1 µm diameter, 6.5 
µm pitch, and 1 µm depth 
16 - pillars of 250 nm diameter, 




Each dot represents a topography as defined in the figure. The data sets were calculated to have a Pearson 
product-moment correlation coefficient (R) of -0.34 and a coefficient of determination (R2) of 0.11. We 
can see this low negative correlation represented in the scatter plot.   
 
 
Figure 16 Scatter plot showing low negative correlation between the mean normalized transfection efficiency and mean 
normalized final cell density. Each dot represents results from one topography of the MARC chip. The line of best fit (black) 
has R = -0.34 and R2 = 0.11.  
 
 In the scatter plot of mean normalized transfection efficiency versus mean normalized final cell 
density (Figure 16), there are three clusters that each closely follow different trend lines. These clusters 
are more clearly shown on separate graphs in Figure 17. We were curious to see if the topographies in 
each cluster were related in some way. We considered their geometry (lenses, pillars, gratings or holes), 
height (h, > 300 nm or ≤ 300 nm), height to width aspect ratio (h/w, > 0.3 or ≤ 0.3), size scale (nano or 
micro), and average cell area (> 0.0042 mm2 or < 0.0042 mm2; 0.0042 mm2 was the average cell area on 
unpatterned areas of the MARC chip) (Table 2). Different geometries were dispersed among all three 
clusters. Interestingly, 5 out of the 6 patterns in cluster 1 had height ≤ 300 nm and 3 out of the 4 patterns 
in cluster 2 have height ≥ 700 nm while cluster 3 had topographies with height ranging between 40 nm 
and 2 µm. Clusters 1 and 3 had a mix of high and low average cell area as well as micro and nano-scale 
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topographies. Cluster 2, however, uniquely contained micro-scale topographies that also cause low 




Figure 17. Clusters found within the scatter plot of mean normalized transfection efficiency versus mean normalized final 
cell density. (A – C) Three different clusters of data on the scatter plot of mean normalized transfection efficiency versus mean 
normalized final cell density. (A) Cluster 1 follows a trend line with R = -0.96 and R2 = 0.92. (B) Cluster 2 follows a trend line 
with R = -0.99 and R2 = 0.99. (C) Cluster 3 follows a trend line with R = -0.82 and R2 =0.67. Each dot represents results from one 






A Cluster 1 B Cluster 2 
C Cluster 3 
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Table 2 Comparison of the characteristics of topographies in clusters found within the scatter plot of mean normalized 
transfection efficiency versus mean normalized final cell density.  Topographies were considered Nano if all of their features 
(width, height, and spacing) were less than 1µm and were considered Micro if at least one of their features was greater than 1µm. 
High average cell area is defined as > 0.0042 mm2. Low average cell area is defined as < 0.0042 mm2. 0.0042 mm2 was the 









The correlation between cell area and transfection efficiency was also examined. The scatter plot 
in Figure 18 shows the mean normalized transfection efficiency observed on each topography of the 
MARC chip versus average cell area observed on each topography. Each dot represents a topography as 
defined in the figure. The data sets were calculated to have a correlation coefficient of 0.38. We can see 
this low positive correlation represented in the scatter plot.   
 
Figure 18. Scatter plot showing low positive correlation between the mean normalized transfection efficiency and average 
cell area. Each dot represents results from one topography of the MARC chip. The line of best fit (black) has R = 0.38 and R2 = 
0.14.  
 
Principal component analysis was performed on measurements of normalized transfection 
efficiency, normalized average cell area, and normalized cell density, from five different MARC chips, as 




The work covered in this chapter first looks at the fabrication and characterization of the 
patterned PDMS substrates. SEM images showed that all patterns were successfully replicated onto the 
PDMS substrates. The width and spacing of the topographical pattern # 1, designed to be gratings with 
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250 nm width, spacing, and height, were inconsistent. This was likely due to the merging of multiple 
gratings on the PDMS mold before fabrication of substrates. Lateral collapse or pairing is a common 
problem with PDMS gratings, most commonly seen in high aspect ratio PDMS topographies111-113. Using 
PDMS with a higher ratio of curing agent to base might help mitigate this problem. The width and 
spacing of other topographical features were as expected. For more precise verification of the fidelity of 
topographical feature height, other techniques would be required. Techniques that could be used to 
measure the height of these features are atomic force microscopy (AFM) or digital holographic 
microscopy (DHM). For our purposes, we were satisfied with seeing the presence of the topographies and 
that they were predominantly as expected.  
Next, we set out to define the experimental parameters we would use for our studies of 
Lipofectamine-mediated transfection of hMSCs on PDMS substrates. This involved selecting the ratio of 
DNA to Lipofectamine to use for our transfections and determining the seeding density to achieve 
appropriate hMSC confluency on PDMS substrates. After testing a few DNA (µg) to Lipofectamine (µl) 
ratios, 1:0.4 was found to be an effective ratio for Lipofectamine transfections and was therefore used in 
all subsequent tests. A seeding density of 8000 cells/cm2 was found to give close to 50 % confluence 
which was deemed appropriate. It was also verified that the change in confluence between a seeding 
density of 5000 cells/cm2 and 8000 cells/cm2 did not affect the transfection efficiency.  
It was repeatedly observed that on a single sample, areas of abnormally high or low cell 
confluence caused large variations in transfection efficiency (Figure 19 A and B). Areas of 95-100 % 
confluence had extremely low transfection compared to the average transfection efficiency of the sample, 
while areas with greater than 0 % and lower than 10 % confluence tended to have inflated transfection 
efficiency. This is not surprising since confluent cells have a slower growth rate which impedes 
transfection as cell division is required for Lipofectamine-mediated transfection 86, 114.  
The fluctuation in cell density might not affect statistical analysis if we have a sufficiently large 
population of cells on a large cell culture area. However, it is a concern when working with the MARC 
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chip as each pattern is confined to a small area of the substrate. If this area happens to have too many or 
too few cells compared to the rest of the substrate, due to uneven seeding, then the data on transfection 
efficiency for that pattern could be strongly influenced by cell density causing increased variance. Hence, 
we made extra effort to ensure seeding on MARC chip substrates was even across each patterned area of 
the sample. Even seeding was more easily achieved with a seeding density of 8000 cells/cm2 rather than 
5000 cells/cm2 which confirmed our choice of seeding density. 
 
  
Figure 19. Variation in transfection efficiency seen in areas of a sample with abnormally high or low cell confluence.  (A) 
Low percentages of EGFP (green) transfection resulting from abnormally high cell confluence and (B) high percent transfection 
resulting from abnormally low cell confluence due to uneven seeding of a sample seeded at 5000 cells/cm2 on unpatterned 
PDMS. Cells are stained with Alexa Fluor 546 Phalloidin (red) and DAPI (blue). Scale bars are 100 µm. 
 
Transfection experiments on the MARC chip allowed us to select topographical patterns for 
further study based on trends that were seen in the transfection efficiency. Five of the selected 
topographies were selected based on their positive effect on transfection efficiency. These were 250 nm 
gratings (pattern # 1), 1 µm gratings with 2 µm spacing (pattern #5), 1 µm concave lenses (pattern # 10), 
1 µm holes (pattern # 15), and 250 nm pillars (pattern # 16).  
We looked at the effect that the topographies had on cell surface density to see if there would be a 




transfection efficiency and cell density with a correlation coefficient of -0.34. In particular, it was 
interesting to see that 1 µm concave lenses (pattern # 10) increased mean transfection efficiency while 
decreasing cell density, while the inverse pattern (# 11, 1 µm convex lenses) showed a slight decrease in 
transfection efficiency and a slight increase in cell density. Hence, pattern 11 was also included for further 
study to compare to pattern 10 to determine the effect of direction of curvature of 1 µm lenses on 
transfection efficiency and cell density.  
Finally, we looked at the effect that the topographies had on average cell area to see if there 
would be a correlation between this and transfection efficiency. Overall there was a low positive 
correlation between transfection efficiency and average cell area with a correlation coefficient of 0.38. An 
equal number of topographies that had decreased cell area, were seen to have increased and decreased 
transfection efficiency.  However, three of the five topographies that showed increased average cell area 
also showed increased transfection efficiency including gratings of 2 µm diameter, 1µm spacing, 80 nm 
height (pattern # 6), 1 µm concave lenses (pattern # 10), and 250 nm pillars (pattern # 16). Two of these 
patterns (pattern # 10 and # 16) were already selected for further study. Although cell area did not 
strongly correlate with transfection efficiency, it would be interesting to continue to monitor cell area in 
future studies especially on 1 µm concave and convex lenses (pattern # 10 and # 11) which again showed 
opposite effects.  
It is important to note that no statistically significant differences were seen in the MARC chip 
data on transfection efficiency or final cell density, and very little statistical significance was seen in the 
MARC chip data on cell area. This is not surprising, due to the nature of these small sample areas. To 
determine statistical significance, further study should be done on single-patterned substrates with larger 
patterned areas.  
A subset of topographies showing a linear relationship between transfection efficiency and cell 
density (with R = -0.99) shared characteristics of micro-scale dimension, caused decreased average cell 
area (compared to unpatterned areas of the MARC chip), and had normalized cell densities ≥ 1.59. Three 
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out of 4 of these topographies also had height ≥ 700nm. Also, topographies showing a different linear 
relationship between transfection efficiency and cell density (with R = -0.96) all had normalized cell 
densities ≤ 1.07. Five out of 6 of these topographies had height ≤ 300 nm. This supports that there may be 
a relationship between (i) topography size, (ii) cell spreading, (iii) cell density, and (iv) the relationship 
between cell density and transfection efficiency, which could not be quantified in this work.   
 Other studies in the literature have also investigated topography influence on non-viral 
transfection. One study investigated nano- and micro-topographical patterns fabricated on PMMA 
substrates including pillars with 2 µm diameter and height (similar to pattern 14 in our study), pillars with 
200 nm diameter and 400 nm height (most similar to pattern 16 in our study, but with larger spacing 
between pillars), and gratings with 250 nm width and height (similar to pattern 1 in our study)17. They 
tested topography effects on Lipofectamine-mediated GFP transfection of hMSCs and found that the 
highest transfection efficiency occurred on nano-pillars and that the enhancement was statistically 
significant compared to their unpatterned control. Their 2 µm pillars and 250 nm gratings also showed 
increases in transfection efficiency, however these were not determined to be statistically significant. In 
our study, we also found that nano-gratings (pattern 1) and nano-pillars (pattern 16) caused an increase in 
transfection efficiency. This shows that these topographies can increase transfection efficiency whether 
the substrate material is PMMA or PDMS, and encourages further study of these topographies on large 
substrates to determine whether our results could show statistical significance. We did not, however, find 
that 2 µm pillars (pattern 14) caused any increase in transfection efficiency. In their study this topography 
showed the lowest increase, and differences between our results and theirs could be due to variability 
since neither our results nor theirs showed statistical difference compared to unpatterned controls.  
 Studies have also looked into topographical influence on endocytosis. One study showed that 
human fibroblasts on PMMA nano-columns (160nm height, 100nm diameter, and 230nm pitch) would 
attempt to internalize the columns through clathrin-mediated endocytosis88. Also, the previously 
mentioned study found that micro- and nano-pillars could increase internalization of dextran by hMSCs 
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and monkey kidney fibroblasts (COS7), which suggests that these topographies increase the rate of 
micropinocytosis17. Lipoplexes specifically have been found to enter cells by clathrin-mediated 
endocytosis, however other transfection reagents have been shown to depend on other types of 
endocytosis, such as polyplexes which depend on both clathrin- and caveolae-mediated endocytosis115, 116. 
Due to the observations in our study and in literature that nano-pillars can increase transfection efficiency 
as well as the observation in literature that nano-pillars appear to induce clathrin-mediated endocytosis, it 
is a possibility that the increased transfection is caused by the enhancement of endocytosis. This 
relationship would need to be further studied to find evidence of causation.  
Another study screened a library of 160 different micro-scale pit geometries on PDMS substrates 
and found that the efficiency of Lipofectamine-mediated GFP transfection of human dermal fibroblasts 
could be improved 25% with pits of 4µm with and 1µm spacing compared to unpatterned substrates16. 
Our observation that holes of 1 µm diameter, 6.5 µm pitch, and 1 µm depth (pattern 15) increased 
transfection efficiency may relate to these findings. Their findings showed that pits with 1 µm diameter 
and 4µm spacing (a topography more similar to our pattern 15) increased the percentage of transfected 
cells compared to unpatterned controls, however this increase was not found to be statistically significant. 
This encourages the idea of pursuing further study of the effect that pattern 15 has on non-viral 
transfection of hMSCs, and possibly comparing the effects of this pattern to the effects of holes with 













This chapter focuses on the methods and results of experiments investigating the effects of nano- 
and micro-topography on neuronal transdifferentiation of hMSCs induced by non-viral delivery of BAM 
(Brn2, Ascl1, and Myt1l) transcription factors. In these investigations, poly(N,N-cystaminebisacrylamide-
4-amino-1-butanol) (pABOL) was used as the non-viral transfection reagent because of its potential to be 
translated to clinical applications. The protocol used in these experiments to induce transdifferentiation 
was adapted from a method described previously to induce neuronal cells from fibroblasts 15, 20. This 
protocol uses serial dosing of polyplexes followed by an induction period. First tests were done on 
unpatterned substrates to optimize the transdifferentiation test conditions and then transdifferentiation was 
carried out on the MARC chip to investigate topographical influence. 
As cells convert to neurons, they are expected to become post-mitotic. Hence, it was important to 
consider our initial cell seeding density before the transdifferentiation process to ensure a reasonable 
number of cells would remain by the end of the 2-3 week process. To increase the chances of having a 
desirable number of cells at the end, we were inclined to increase the seeding density, however, this could 
have detrimental effects on transfection efficiencies due to contact inhibition if high confluence were 
reached 86, 117. Therefore, to determine a reasonable seeding density for our studies, we investigated the 
effect that an increased seeding density of 12000 cells/cm2 would have on final cell density and 




The dose of polyplex delivered at each transfection was also evaluated. Dosage can affect cell 
viability as well as the percentage of transfected cells in the final cell population. An ideal dosage would 
result in the highest possible number of transfected cells per area by balancing high transfection 
efficiency with cell health. The alamarBlue toxicity assay and phase contrast imaging were used to 
determine the impact of different doses on hMSC viability. Flow cytometry was used to measure the 
impact of different doses on the final percentage of transfected cells. Estimations were then made to 
determine which dose resulted in the overall largest final population of transfected cells per area. 
Transdifferentiation was then carried out with the determined dosage and cell density on MARC 
chips to screen for topography-effects on the success of conversion. Immunofluorescence (IF) staining 
was used to analyze the presence of the neuronal marker, MAP2, after transdifferentiation as well as 




3.2.1. Fabrication and Characterization of Substrates 
 
MARC chip and unpatterned PDMS chamber substrates were the same type as the ones used in 
experiments described in Chapter 2. Their fabrication has been described in section 2.2.1 and their 






3.2.2. Cell Culture and Substrate Preparation  
 
Cell culture and substrate sterilization were carried out in the same ways as described in section 
2.2.3. However, for transdifferentiation, the substrates were additionally coated with fibronectin from 
bovine plasma (Millipore Sigma) prior to cell seeding. The fibronectin was diluted in PBS and added to 
substrates at 1µg/cm2. Coating was carried out for 2 hours at 37 °C in the incubator. The excess 
fibronectin solution was removed from substrates before cell seeding.  
 
3.2.3. BAM Factor Plasmid Amplification and Purification 
 
Ascl1 and Myt1l-expressing plasmids (Invitrogen) were received from Professor Kam W. 
Leong’s group at Columbia University. Brn2-expressing plasmid were cloned at the National University 
of Singapore by Dr. Christopher L. Grigsby of Professor Kam W. Leong’s group at Columbia University. 
Plasmids were amplified as described in section 2.2.4, but with GT116 cells (InvivoGen), Blas TB Broth 
(InvivoGen), and Blas LB Agar (InvivoGen). They were then purified using a QIAGEN Plasmid Midi 
Kit. Final purified plasmid concentration was measured with a NanoDrop ND-1000 Spectrophotometer.  
 
3.2.4. Transfection Using pABOL Polyplexes 
 
Plasmid DNA was first diluted in pABOL buffer, composed of 20mM HEPES (Gibco) with 5 
weight percent glucose (Sigma) in molecular grade water (Sigma), at a concentration of 75 µg/ml. When 
BAM plasmids were being used, they were combined at an equimolar ratio. pABOL was fabricated and 
given to us by Professor Kam W. Leong’s group at Columbia University as a solid lyophilized product. 
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This was constructed into a stock solution by dissolving it at 50 µg/µl in molecular grade water. For 
transfections, pABOL was diluted to 844 µg/ml in pABOL buffer. Both diluted DNA and pABOL 
solutions were vortexed briefly and then added together at a 45:1 polymer:DNA mass ratio and vortexed 
for 20 seconds to form polyplexes. The media of samples to be transfected was changed to pre-warmed 
(37 °C) Opti-MEM (Gibco) in advance and polyplex was added to the media at the specified dose 
followed by a 4 hour transfection incubation at 37 °C in the incubator. After this incubation, the media 
was changed back to MesenPRO RS medium. 
 
3.2.5. Cell Fixing and Immunofluorescent Staining  
 
Before fixing, samples were washed once with PBS. They were then fixed in filtered pH-adjusted 
4 % (w/v) PFA (Sigma-Aldrich) for 15 minutes and washed once again with PBS. Cells were then 
permeabilized with 0.1% (v/v) TritonX-100 (Sigma) for 15 minutes and washed once with tris-buffered 
saline (TBS, Fisher BioReagents). Blocking was done in blocking medium containing 1% (w/v) bovine 
serum albumin (BSA, Sigma) and 10% (v/v) goat serum (Lifetech) at 4 °C overnight. Primary antibody 
incubation with anti-MAP2 (abcam), Anti-β-Tubulin III (Millipore Sigma), or Anti-Synapsin I (abcam) 
were done at 1:500, 1:5000, and 1:500 dilution in TBS with 1% goat serum respectively. Primary 
antibody incubation was done at 4 °C overnight. Samples were then washed once with washing buffer, 
composed of 0.05% triton-X and 1% goat serum in TBS, and then  incubated with secondary antibodies 
Alexa-Fluor 546 goat anti-rabbit (Invitrogen) and/or Alexa-Fluor 488 goat anti-mouse (Invitrogen) both at 
dilution 1:1000 in TBS at 4 °C overnight. The next day, samples were washed once with TBS and stained 
with DAPI at a dilution of 1:2500 in TBS for at least 1 hour at room temperature. Finally cells were 




3.2.6. Determining Appropriate Seeding Density for Transdifferentiation 
 
In order to investigate the effect of increased seeding density on final cell density and transfection 
efficiency after serial transfections, hMSCs were seeded at 5000 and 12000 cells/cm2 on PDMS and glass 
substrates. The cells were transfected with 0.5 µg/cm2 EGFP-expressing plasmid three times at 48 hour 
intervals according to the timeline below (Figure 20). Transfections were done with both polyplex (3.2.4) 
and Lipofectamine (2.2.5 with a 1:0.4 plasmid (µg) to Lipofectamine (µl) ratio). Samples were stained 
with Alexa Fluor 546 Phalloidin and DAPI and then imaged by fluorescence microscopy (as described in 
section 2.2.5). Cell density and the percentage of cells expressing EGFP were quantified using ImageJ 
software.  
 
        
Figure 20 Timeline for serial transfections. Analysis on day 6 involved fluorescence imaging (of DAPI and phalloidin staining 
as well as EGFP expression)  for studies determining appropriate seeding density (section 3.2.6) and involved the alamarBlue 
assay, fluorescence imaging (of EGFP expression only), and flow cytometry for studies determining polyplex dosage effects on 
cell viability and transfection efficiency (section 3.2.7 and 3.2.8).  
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3.2.7. AlamarBlue Assay to Determine Polyplex Dosage Effects on Cell Viability after Serial 
Transfections 
 
AlamarBlue is a cell viability indicator that uses the reducing power of living cells to convert 
resazurin to the fluorescent molecule resorufin (Figure 21). The amount of fluorescence produced in cell 
culture medium after incubation with alamarBlue is proportional to the number of living cells in the 
culture and the incubation time. AlamarBlue reagent was added as 10% of the sample volume and then 
incubated for a set amount of time. After incubation, the fluorescence intensity was measured for each 
sample. Additionally, samples with 100% reduction were made by autoclaving media containing 10% 
alamarBlue reagent and negative controls (with 0% reduction) were made by incubating a sample of 
media containing 10% alaramBlue with no cells along with test samples. From fluorescence readings, the 
percent of alamarBlue that was reduced by living cells in each sample (% reduction) was calculated using 
the formula below (Equation 3.1). 
 
 
Figure 21. Resazurin conversion to resorufin. Resazurin (left) is the molecule in alamarBlue that becomes the fluorescent 
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The appropriate incubation time for the alamarBlue assay can change depending on the cell line 
being studied 119.To ensure that we were using an appropriate incubation time for our study, hMSCs were 
seeded in tissue culture plates at various densities around the expected density of our experiment samples 
(500, 2000, 5000, 8000, & 12000 cells/cm2). Twenty-four hours after seeding, alamarBlue was added to 
the wells. The samples were then returned to the incubator and fluorescence was measured at 2, 4, 6, 8, 
and 24 hours with 530-560nm excitation and 590nm emission. Plots of percentage of reduction versus 
seeding density for various incubation times allowed us to find an appropriate incubation time.  
To determine the effect of three different polyplex dose sizes on hMSC viability, cells were 
seeded at 8000 cells/cm2 and then transfected three times with either a dose of 0.25, 0.5, or 1 µg 
plasmid/cm2 according to the timeline shown in Figure 20. This was done on unpatterned PDMS 
substrates. Lipofectamine transfection with the 0.5 µg/cm2 dose and non-transfected samples were used as 
positive and negative controls respectively. Additionally, to control for substrate material effects, 
polyplex and Lipofectamine transfection with a 0.5 µg/cm2 dose and non-transfected controls were 
carried out on tissue culture polystyrene (TCPS). Twenty-four hours after the last transfection, 
alamarBlue was added to the samples followed by a 7 hour incubation. Finally, fluorescence intensity 
measurements of the cell culture media (with 530-560nm excitation and 590nm emission) were taken and 
the percentage of reduction was calculated. The percentage of viability was then calculated for each 
sample as the percentage of reduction from the test condition over the percentage of reduction from 




 % Viability =
% Reduction from Test Condition
% Reduction from Untreated Sample
× 100 (3.2) 
 
3.2.8. Determining Polyplex Dosage Effects on Transfection Efficiency and Transfected Cell 
Density after Serial Transfections 
 
To determine the effect that polyplex dosage has on transfection efficiency after three serial 
transfections, samples that were prepared for the alamarBlue assay, as described in section 3.2.7, were 
examined with fluorescence imaging to view the EGFP expression over large surface areas and by flow 
cytometry to measure the percentage of the cell population expressing EGFP. Doses of 0.25, 0.5, or 1 µg 
plasmid/cm2 were tested. Twenty-four hours after the last transfection, samples were imaged without any 
staining to acquire large mosaic images representing the surface density of EGFP-expressing cells. Cells 
were then detached with TrypLE Express (Gibco), resuspended in media and counted. To fix the cells for 
flow cytometry, they were then spun down to remove media and resuspended in 500 µl of cold PBS. Then 
500 µl of cold 2 % PFA was added followed by an incubation for 30 minutes at 4 °C. After fixing, cells 
were spun down at 4 °C to removed supernatant, washed once with cold PBS, resuspended in PBS and 
placed in fluorescence-activated cell sorting (FACS) tubes. Flow cytometry data was analyzed with 
FlowJo software. Gating was based on negative controls which were non-transfected hMSCs grown on 
TCPS substrates and positive controls which were hMSCs transfected three times with 0.5 µg/cm2 
plasmid with Lipofectamine.  
Resulting measurements of EGFP positive percentages of cell populations from each condition 
were then combined with data from the alamarBlue assay (which gave us the number of live cells per 
area) to calculate the concentration of EGFP positive cells per area resulting from each condition. This 
calculation was done using the equation shown below (Equation 3.3). 
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3.2.9. Transdifferentiation on PDMS MARC Chip Substrates 
 
 To induce neuronal transdifferentiation of hMSCs, cells were first seeded at 12000 cells/cm2 in 
MesenPRO RS medium (Gibco). The cells were given 36 hours in the incubator to adhere and adjust to 
their substrate. The hMSC growth medium was changed 24 hours after seeding. Cells were transfected 
three times with 0.25 µg/cm2 of plasmid DNA delivered by polyplex according to the procedure described 
in section 3.2.4. Each transfection was separated by 48 hours as shown in the timeline below (Figure 22). 
Forty-eight hours after the last transfection, the complete volume of media in each sample was switched 
to N3 neuronal induction media composed of DMEM/F-12 (Gibco) with 25 µg/mL bovine insulin 
(Gemini Bio-Products), 50 µg/mL human apo-transferrin (Gemini Bio-Products), 30 nmol/L sodium 
selenite (Millipore Sigma), 20 nmol/L progesterone (Millipore Sigma), 100 µmol/L putrescine (Millipore 
Sigma), 10 ng/mL human basic fibroblast growth factor (Gibco), and 25 µg/mL gentamicin (Gibco). Cells 
were maintained in neuronal induction medium for 10 days and eighty percent of the medium was 
changed every 48 hours until cells were fixed and stained as described in section 3.2.5. 





    
Figure 22 Timeline for inducing neuronal transdifferentiation of hMSCs. The process of neuronal induction involves a 
transfection phase and an induction phase (red).  First hMSCs were seeded at 12000 cells/cm2 on MARC chip substrates (PDMS) 
and unpatterned control substrates (PDMS and glass) in MesenPRO RS medium. The first transfection occurred 36 hours after 
seeding and the next two transfections followed every 48 hours. On day 7, media was switched to neuronal induction media. On 
day 17, samples were fixed and stained for immunofluorescent imaging. 
 
3.2.10. Statistical Analysis 
 
Statistical analyses were performed using a one-way ANOVA test with Tukey’s multiple 
comparisons test or using an unpaired t-test using Prism (GraphPad). All values are presented with mean 
values ± standard deviation. Statistical tests were considered significant when P ≤ 0.05 (noted by *), P ≤ 
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3.3.1. Selecting Appropriate Seeding Density for Transdifferentiation 
 
Fluorescence images taken after serial EGFP transfections of hMSCs seeded at 5000 and 12000 
cells/cm2 (Figure 23) allowed us to see the effect that this difference in seeding density had on final cell 
density (Figure 24) and percentage of transfected cells in the final cell population (Figure 25). On glass 
substrates, an initial seeding density of 5000 cells/cm2 was sufficient for a final cell density of at least 
3000 cells/cm2. However, at this seeding density on PDMS substrates the final cell density was extremely 
low, around 1000 cells/cm2. The higher seeding density of 12000 cells/cm2 ended in final cell density of 
over 10000 cells/cm2 on glass samples, and a good density of over 5000 cells/cm2 on PDMS substrates. 
From this experiment, we observed that the final cell density was dependent on the initial seeding density 
and substrate material. 
 
 
Figure 23 Fluorescence images of cells seeded at 5000 and 12000 cells/cm2, after three serial transfections. (A) 
Lipofectamine-mediated transfection. (B) Polyplex-mediated transfection. Cells were initially seeded at 5000 or 12000 cells/cm2 
on glass (top row) or PDMS (bottom row) substrates. Cells were transfected with EGFP (green) and stained with Alexa Fluor 546 















     
Figure 24 Quantification of final cell densities of cells seeded at 5000 or 12000 cells/cm2, after three serial transfections. 
(A) Lipofectamine-mediated transfections on glass substrates. (B) Polyplex-mediated transfection on glass substrates. (C) 
Lipofectamine-mediated transfections on PDMS substrates. (D) Polyplex-mediated transfections on PDMS substrates. n=3. ** 
and **** denote statistical significance with P ≤ 0.01 and P ≤ 0.0001 respectively. 
 
Although the higher seeding density was necessary for samples with PDMS substrates, the 
transfection efficiency on each sample was quantified to ensure that the increased seeding density would 







transfected. It was found that the percentage of transfected cells was not significantly affected by the 
difference in seeding density (Figure 25). The mean final percentages of cells that were transfected ranged 
between 2.9 % ± 1.7 % and 7.2 % ± 5.7 % on glass substrates and between 5.1 %  0.8 % and 9.4 %  5.1 
% on PDMS substrates.  
     
Figure 25 Quantification of percentage of transfected cells after seeding at 5000 or 12000 cells/cm2 followed by three serial 
transfections. (A) Lipofectamine-mediated transfections on glass substrates. (B) Polyplex-mediated transfection on glass 
substrates. (C) Lipofectamine-mediated transfections on PDMS substrates. (D) Polyplex-mediated transfections on PDMS 







A seeding density of 12000 cells/cm2 was therefore used in our transdifferentiation studies as it 
resulted in a higher final density and did not affect the percentage of transfected cells on PDMS substrates 
after serial transfections.  
 
3.3.2. Effect of Polyplex Dosage on Cell Viability 
 
Before using the alamarBlue assay to measure cell viability, the appropriate incubation time for 
the alamarBlue assay was determined. Plotting percentage of reduction versus seeding density showed 
that any incubation time between 2 and 8 hours would allow us to linearly correlate the measured 
percentage of reduction of a sample to the density of viable cells in the sample using the alamarBlue assay 
(Figure 26). With a longer incubation, smaller cell densities can be detected, therefore an incubation time 
of 7 hours was used for our alamarBlue assays.   
             
Figure 26. Plots of percent reduction versus seeding density for various alamarBlue incubation times. 
 
The measurements of percent viability from the alamarBlue assay results showed that a 0.25 
µg/cm2 dose of DNA delivered by polyplex was less toxic to hMSCs compared to higher doses after three 
serial transfections; however, no significant difference was observed (Figure 27). It was also notable that 
samples transfected with Lipofectamine tended to have higher average percent viability, and in some 
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cases the difference was significant. This, however, did not deter our interest in using the polyplex since 
its advantage is translatability to in vivo clinical applications. The toxicity may be specific to hMSCs 
since it has been shown that fibroblasts transfected with similar doses of the same type of polyplex had 
between 80 and 100 % viability after one or two serial transfections15.  
 
   
Figure 27. Percent viability measurements from alamarBlue assay after three serial transfections. Blue indicates samples 
on PDMS substrates and grey indicates samples on TCPS substrates. n=4. * denotes statistical significance with P ≤ 0.05. 
 
Cell morphology was imaged by phase contrast microscopy before and after the three serial 
transfections, and the cell health, judged by visible blebbing, correlated with the decrease in the mean of 
percentage of cell viability with increasing dose seen in results from the alamarBlue assay (Figure 28). 
Cells transfected with the lowest tested dose of polyplex (Figure 28 A) showed a healthier morphology 
compared to those transfected with higher doses (Figure 28 B and C). However, what was observed to be 
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blebbing might have been aggregates of polyplex, which could be verified by DAPI staining in future 
experiments. Samples transfected with Lipofectamine showed heathier cell morphology and higher cell 




Figure 28 Phase contrast images taken after three serial transfections (on day 6) with different doses of polyplex. Human 
MSCs on PDMS substrates after three serial transfections with (A) 0.25 µg/cm2, (B) 0.5 µg/cm2, and (C) 1 µg/cm2 of EGFP-
expressing plasmid DNA. Scale ars are 250 µm. 
 
 
Figure 29 Phase contrast images taken before and after three serial transfections. Images are shown on both TCPS (top row, 
A to D) and PDMS (bottom row, F to H) substrates. (A and E) hMSCs on day 1 before the first transfection. (B and F) hMSCs on 
day 6 after three polyplex-mediated transfections. (C and G) hMSCs on day 6 after three Lipofectamine-mediated transfections. 
(D and H) Untransfected hMSCs on day 6. All transfections were with a 0.5 µg/cm2 dose of of EGFP-expressing plasmid DNA. 
Scale bars are 250 µm. 
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3.3.3. Effect of Polyplex Dosage on Transfection Efficiency and Final Transfected Cell Density 
 
Flow cytometry showed that there was no statistically significant difference in the percentage of 
cells that were successfully transfected when they were transfected three times with polyplex delivering 
0.25, 0.5, or 1 µg/cm2 doses of DNA (Figure 30). All transfections were done with a polymer:DNA mass 
ratio of 45:1. The mean percentage of EGFP positive cells from samples transfected with a 0.5 µg/cm2 
dose by Lipofectamine was lower than that of the samples transfected with polyplex, however, the 
difference was not found to be statistically significant. 
              
     
Figure 30. Percentages of hMSC population expressing EGFP after serial transfection with varying polyplex dosages. 
Polyplex transfections were done with a pABOL:DNA mass ratio of 45:1. For the control, Lipofectamine transfections were done 
with a Lipofectamine (µl):DNA (µg) ratio of 0.4:1. n=2. 
 
Figure 31 shows the EGFP positive cell populations after three serial polyplex-mediated 
transfections with doses of either 0.25, 0.5, or 1 µg/cm2 DNA (with pABOL:DNA mass ratio of 45:1) and 
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after serial Lipofectamine-mediated transfections with 0.5 µg/cm2 DNA (with Lipofectamine (µl):DNA 
(µg) ratio of 0.4:1) as a positive control. There was comparable EGFP expression per area after polyplex 
transfections with 0.25 and 0.5 µg/cm2 of DNA (Figure 32). A slightly lower EGFP expression per area 
after transfection with 1 µg/cm2 of DNA was observed, which could be because of the lower cell density 
resulting from higher toxicity. The EGFP expression per area from Lipofectamine transfections appeared, 
from these images, to be comparable to that resulting from the 1 µg/cm2 dose polyplex transfections. 
Although flow cytometry measurements showed that Lipofectamine produced a lower percentage of 
EGFP positive cells, Lipofectamine was also less toxic to the cells (Figure 27) which would have 





        
Figure 31. Fluorescence images showing the EGFP positive cell population after three serial transfections with varying 
polyplex dosages. Lipofectamine-mediated transfection with the middle sized dose was used as a control (bottom right). Scale 













                    
Figure 32 Fluorescence intensity measurements of images showing EGFP positive cell population after three serial 
transfections with varying polyplex dosages. Here fluorescence intensity was measured by taking the integrated density 
measurements of the images in Figure 31 with ImageJ software. n =1. 
 
 The table below summarizes the fractions of EGFP positive cells in final cell populations of 
samples transfected with 0.25, 0.5, or 1 µg/cm2 doses of DNA (measured by flow cytometry, Figure 30), 
the number of live cells per area after transfections for each test condition, and the number of transfected 
cells per area calculated by equation 3.3.  
Table 3 Number of transfected cells per area after three serial transfections with varying polyplex dosages. DNA Dose is 
the amount of DNA that was delivered three times to each sample with a Lipofectamine (µl):DNA (µg) ratio of 0.4:1 or a 
pABOL:DNA mass ratio of 45:1. Mean Fraction of EGFP Positive Cells was determined by flow cytometry (n=2, same data as 
shown in Figure 30). Number of Live Cells per area was determined with alamarBlue results (n=4). The Number of Transfected 






Fraction of EGFP 
Positive Cells 





Polyplex 0.25 0.494 ± 0.234 7200 ± 3730 3550 
Polyplex 0.5 0.471 ± 0.075 2250 ± 3630 1060 
Polyplex 1 0.617 ± 0.009 2350 ± 3230 1450 
Lipofectamine 0.5 0.185 ± 0.059 16 080 ± 10 270 2980 
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From the calculated numbers of transfected cells per area, we observed that the mean density of 
transfected cells resulting from serial polyplex-mediated transfections with 0.25 µg/cm2 doses of DNA 
was the highest. The resulting density of transfected cells from Lipofectamine controls was higher than 
from serial polyplex-mediated transfections with 0.5 and 1 µg/cm2 doses of DNA due to the high total 
number of living cells. 
 
3.3.4. Transdifferentiation on PDMS MARC Chip Substrates 
 
 Immunofluorescence staining was similar in all of the unpatterned control samples (Figure 33). 
Slight differences between the non-transfected hMSCs on glass substrates (Figure 33 A) and the positive 
controls on both glass and unpatterned PDMS (Figure 33 B and D) could be observed. Non-transfected 
hMSCs on unpatterned PDMS (Figure 33 C) showed levels of staining visually very similar to both 
positive controls.  
 By visual observation of MAP2 immunofluorescence staining, none of the patterned PDMS 
substrates had an enhancing effect on the expression of MAP2 (Figure 34). Morphological changes could 
be seen as a result of topographical influence. Gratings designed to have height of 2 µm caused cells to 
consistently align along the grating axis. Attachment of cells was also a factor influenced by certain 
topographies. Specifically, gratings, pillars, and wells had similar confluency compared to unpatterned 
controls, while lens topographies resulted in more cell detachment throughout the 10 day induction 









Figure 33. Immunofluorescence images of positive and negative control samples on unpatterned substrates. (A) Non-
transfected cells on glass substrates. (B) Transfected cells on glass substrates. (C) Non-transfected cells on PDMS substrates. (D) 






































Figure 34. Immunofluorescence images of hMSCs treated with transdifferentiation protocol on topographically patterned 
areas of the PDMS MARC chip. Scale bars are 100 µm. Cells are stained with anti-MAP2 (green) and DAPI (blue). 
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The first focus of this work was to set up the baseline conditions to use when inducing neuronal 
transdifferentiation of hMSCs on PDMS substrates. This involved testing parameters such as initial 
seeding density and polyplex dosage on unpatterned substrates before moving on to investigating the 
effect that topographically patterned substrates would have on the cell conversion. To decide on the 
values to use for these parameters we looked into the effect that initial seeding density has on cell density 



























and transfection efficiency of the samples after serial transfections and at the effect that polyplex dosage 
has on transfection efficiency, viability, and overall resulting surface density of transfected cells after 
serial transfections (Figure 20).  
The reasons for testing different initial seeding densities was to find the density that would leave 
us with a sufficient number of cells to analyze after the entire cell conversion process. This is a concern 
because as cells convert to neurons they are expected to become post-mitotic which limits their 
population35. We found that on unpatterned PDMS substrates, an initial seeding density of 12000 
cells/cm2 would leave samples with a cell density of 5098 ± 931 cells/cm2, which was equivalent to ~50 
% confluency, after the transfection period of the cell conversion process. With this density of cells after 
the serial transfections, we were confident that there would be enough cells to analyze even after the 
expected cell death during the following induction phase. When we moved forward with our initial 
transdifferentiation experiments on the MARC chip (results from these experiments were not included in 
results section), we found cells remained above ~30% confluent by the final day of induction. However, 
during fixing of the samples, most of the cells would detach from our substrate due to very weak 
attachment. To mediate this we decided to additionally coat the PDMS substrates with fibronectin before 
seeding and add fibronectin to the media of samples 2 weeks after seeding. With this fibronectin coating, 
cells remained above ~30% confluent throughout and did not detach during fixing or staining.    
Since we decided on using a seeding density of 12000 cells/cm2, it was important to ensure that 
this would not have detrimental effects on the transfection efficiency. As we have discussed in the 
previous chapter, high cell density can reduce transfection efficiency due to contact inhibition. We found 
that when compared to using a standard seeding density for hMSCs of 5000 cells/cm2, there was no 
significant difference in the resulting transfection efficiency after serial transfections. Hence, we were 
confident in deciding to use a seeding density of 12000 cells/cm2 for our transdifferentiation experiments 
on PDMS substrates.  
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Because of the strong positive and negative correlations that dosage can have with transfection 
efficiency and cell viability, respectively, we sought to tune the dosage we would use in our experiments 
to balance these two important factors. Achieving this balance would effectively maximize the final 
surface density of transfected cells. From phase contrast imaging and the alamarBlue assay after three 
serial transfections, we found that cells showed healthier morphology and there were a higher number of 
living cells in samples that were transfected with a 0.25 µg/cm2 dose of DNA delivered by polyplex 
(although this was not statistically significant). The transfection efficiency was not significantly different 
between samples transfected with the different doses of polyplex. When the mean transfection efficiencies 
and the cell counts were used to calculate the number of transfected cells per area, the two higher doses 
had very similar results while the lower dose resulted in a higher final number of transfected cells. With 
this information we determined that using the lowest dose (0.25 µg/cm2) was beneficial, and chose to 
move forward using this dose in all subsequent experiments. It can be noted that a higher dose (1 µg/cm2) 
resulted in transfection efficiencies with less variability between repeat samples compared to lower doses, 
which may be beneficial to consider in future studies. 
In the literature, poly(amido amine)s containing repetitive disulfide linkages, like the p(ABOL) 
used in our study, were designed to be highly efficient intracellularly degradable gene delivery vectors. 
They were found to be relatively stable in the extracellular setting but were prone to fast degradation in a 
reductive environment analogous to that in the cytoplasm82. The balance between extracellular stability 
and intracellular unpacking was expected to support high transfection efficiency and reduce toxicity of the 
polymer vector. As transfection reagents, these polymers have been shown to be essentially nontoxic and 
have transfection efficiencies significantly higher than those of branched polyethylenimine (pEI, a gold 
standard polymeric gene carrier). These studies were done on COS-7 cells (fibroblast-like cells derived 
from monkey kidney tissue). Poly(ABOL) was used to non-virally transfect mouse embryonic fibroblasts 
with BAM transcription factors in order to induce neuronal transdifferentiation15. Due to the transfection 
reagent’s low toxicity, they were able to use repeated dosing which they hypothesized would be a 
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requirement to generate induced neurons efficiently. Using a polymer:DNA mass ratio of 45:1, they found 
that serial delivery of 0.5 µg/cm2 was almost entirely nontoxic compared to untransfected controls. A 
second dose after 48 hours did not show any compounding toxicity. Hence, they used serial transfections 
with this dose to induce neuronal transdifferentiation and produced up to 7.6 % Tuj1 (neuron-specific 
class III β-tubulin) positive cells. In contrast to their results, we found that polyplex delivered to hMSCs 
three times at 48 hour intervals caused higher toxicity. Even delivering doses of only 0.25 µg/cm2 (with a 
polymer:DNA mass ratio of 45:1) resulted in less than 20 % viability. They were also able to achieve 
transfection efficiencies of ~70 % and ~80 % GFP positive cells by transfections with 0.5 µg/cm2 doses or 
1 µg/cm2 after one or two doses. In contrast, we only achieved ~60 % GFP positive cells by transfection 
with 1 µg/cm2 after three doses.  
The lower transfection efficiency and viability that we saw, in comparison to this literature, could 
have been due to the fact that we were using hMSCs rather than fibroblasts or COS-7 cells.  Another 
study in the literature studied the effect of the overall net charge of bioreducible PAAs composed of 
repeating units of cystamine bisacrylamide (CBA), 4-aminobutylguanidine (AGM), and 4-aminobutanol 
(ABOL) on human embryonic kidney 293 (HEK 293) cells, mesenchymal stem cells (MSC)s, and A2780 
human ovarian carcinoma120 . They controlled the net charge of their polymers by adjusting the 
percentage of AGM, the primary source of cationic charge, relative to ABOL within the polymer. They 
found that higher transfection could be achieved in MSCs and HEK 293 cells when the poly(CBA-
ABOL/AGM) contained a higher AGM:ABOL ratio, whereas, the ratio of AGM:ABOL was less critical 
for high transfection of A278 cells. This demonstrates that different cell types can react differently to 
specific transfection reagents depending on their overall net charge and that a co-polymer with a high 
content of ABOL (lower net charge), like the one used in our study, is less effective on MSCs than on 
some other cell types. They also showed that higher mass ratios of polymer:DNA were more toxic to 
hMSCs compared to lower ratios and that the poly(amido amine) caused higher toxicity in hMSCs 
compared to HEK 293 cells. 
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Two studies that focused specifically on developing a transfection reagent to use on hMSCs, 
evaluated arrays of poly(β-amino esters) (PBAEs) with different end groups121, 122. The first paper looked 
at plasmid DNA transfection in different cell types and saw that different end-groups would change 
transfection efficiency drastically in a cell-type specific manner121. They found that a polymer composed 
of repeating units of 1,4-butanediol diacrylate and 5-amino-1-pentanol capped with a specific amine 
capping molecule mediated significantly higher transfection in hMSCs than Lipofetamine 2000. The other 
study found a synthetic end-modified PBAE optimized for small interfering RNA (siRNA)  delivery to 
hMSCs122. Cyctamine-terminated PBAEs were the most effective, achieving 91% knockdown via RNA 
interference. These studies suggest that poly(β-amino esters) with specifically selected end groups may be 
a good alternative transfection reagent option for transfection of hMSCs.   
The second focus of this work was to test transdifferentiation on unpatterned substrates and 
MARC chip substrates. The success of transdifferentiation was analyzed by checking for expression of 
neuronal markers by immunofluorescence staining and change in cell morphology. We could not 
conclude that any induced neurons were produced in any of our samples. Weak signal of 
immunofluorescent-staining of MAP2 appeared in treated samples as well as negative controls. Specific 
MAP2 immunofluorescence staining will stain the microtubule structure of neurons. In our imaging, we 
did not specifically see staining of cytoskeletal filaments, and hence the staining did not appear to be 
specific. There is a chance that the signal seen was a combination of weak MAP2 expression and non-
specific staining. 
One explanation for the similarity in staining across all of the samples and specifically for the 
staining that appeared on the negative controls is that hMSCs are capable of weakly expressing MAP2 
without any specific induction, while increased levels can be seen after induction123, 124 . This low 
expression could be what we are seeing across our negative controls and test samples. However, in that 
case we could have expected to have seen an increased expression of MAP2 in treated samples simply 
from effects of the induction medium. Another hypothesis for why staining was similar across all of the 
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samples could be that it was due to the influences on these cells caused by the high confluence that was 
reached by the end of the transfection phase. 
As we observed from phase contrast images that were taken periodically throughout the 
transdifferentiation treatment, the cells became 100% confluent by the end of the transfection period 
(Figure 35) and then became less confluent during the induction phase (Figure 36 and Figure 37). 
Although cell density at the end of the transfection period was tested when deciding on initial seeding 
density, those tests were done without coating sample substrates with fibronectin. As was mentioned, we 
later realized fibronectin coating was required, to keep cells from detaching, only once we had begun 
transdifferentiation experiments. The addition of fibronectin coating could have been the cause of the 
increased confluence that was observed. One way in which high confluence could have affected the 
conversion process is by decreasing the rate of transfection. As was seen in Chapter 2 and has been 
documented in other literature, high confluence can reduce the efficiency of non-viral transfection86 . 
Alternatively, we question whether the physical impact of high confluence on hMSCs could be causing 
differential gene expression through mechanotransduction. In previous studies, it has been shown that 
physical factors which cause alignment and elongation of hMSC morphology can also cause increased 
MAP2 expression due to spatial regulation of focal adhesions 19. The morphology of highly confluent 
hMSCs is reminiscent of this alignment and elongation. Thirdly, the physical forces from high confluence 
may have overpowered topographical influences on the cells. The high confluence did have strong 
influence on the cells’ spatial arrangement that lasted until the end of the induction phase, as can be seen 
in Figure 35 to Figure 37 and Figure 38. Cells on micro-gratings were observably influenced by the 
topography because their spatial arrangement was aligned with the grating axis, however, on other 
topographies it is unclear to what extent the forces from high confluence may have overpowered cell-






Figure 35. Phase contrast images of cell confluence taken on day 8 of transdifferentiation induction. Scale bars are 250 µm. 
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Figure 36. Phase contrast images of cell confluence taken on day 13 of transdifferentiation induction. Scale bars are 250 
µm. 
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Figure 38 Influence on spatial arrangement from high confluence at day 8. These phase contrast images show hMSCs on 1 
µm concave lenses (pattern 10) at (A) day 8, (B) day 13, and (C) day 17 of the neuronal induction protocol. These images show 
the lasting influence that high confluence had on the spatial arrangement of the cells which may have competed with influences 
from topography. Scale bars are 250 µm. 
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In addition to staining for MAP2, attempts were made to identify induced neuronal-like cells by 
staining for Tuj1 and Synapsin1 (this data was not shown in the results section). The first that we tried 
was Tuj1. The staining was bright in our negative control samples. Indeed, high expression of Tuj1 can be 
expected in hMSCs regardless of the number of culture passages and the culture conditions123, 124. Hence, 
we quickly moved on to test alternative neuronal markers. Synapsin1 staining only showed non-specific 






















Non-viral transfection and non-viral transdifferentiation are two processes that are likely to have 
significant impact on the field of regenerative medicine in the near future. Non-viral transfection will 
provide benefits to gene therapies, vaccines, and induction of therapeutically relevant cell types13, 60-62. 
Non-viral transdifferentiation will provide benefits to modeling of diseases and disorders, drug testing, 
and regenerative medicine strategies including cell therapy and tissue engineering125-128. A robust method 
to non-virally transfect cells would give promise for a safe clinically relevant strategy to induce cell 
conversions including transdifferentiation. Non-viral neuronal transdifferentiation specifically, would lead 
to the development of treatments for nerve damage and neurodegenerative diseases. The problem 
remaining with both non-viral transfection and non-viral transdifferentiation is their low efficiency. The 
transition to using non-viral transfection in applications which have routinely been studied using viral 
transfection brings many researched techniques a step closer to clinical applicability by improving their 
safety, however, it is challenging due to their decrease in efficiency. Neuronal transdifferentiation is one 
example of the many researched techniques that has begun to transition from being dependent on viral 
transfection to non-viral transfection for a better chance of becoming a clinically valid technique, but 
suffers more than ever from inefficiency. Therefore, in this thesis project it was our goal to investigate 
whether substrate nano- or micro- topography could (1) increase non-viral transfection efficiency of 
hMSCs and (2) enhance non-viral neuronal transdifferentiation.  
From our studies screening the influence of 16 topographical patterns on non-viral transfection, 
we selected five topographical patterns including nano- and micro-gratings, concave micro-lenses, micro-
holes, and nano-pillars, that increased the average measured transfection efficiency compared to 
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unpatterned substrates, for further study. Convex micro-lenses showed opposite effects on cell density, 
cell area, and transfection efficiency compared to concave micro-lenses. Hence, they were added as a 
sixth topography to our selection of patterns for further study. The results we based these selections on 
did not show statistical significance, but were a hint towards which topographies could be useful to study 
further with more rigorous methods. Quantification of topographical effects on cell density and average 
cell area gave some insight into possible explanations for why certain topographies increased transfection. 
We found some evidence that there may be a relationship between (i) topography size, (ii) average cell 
area, (iii) cell density, and (iv) the relationship between cell density and transfection efficiency. Previous 
studies investigating topography influence on non-viral transfection have looked into the effects of 
PMMA substrates with nano- and micro-pillars and nano-gratings and found that nano-pillars could 
significantly increase non-viral transfection of hMSCs compared to unpatterned substrates17. Another 
study screened 160 different micro-scale pitted geometries on PDMS substrates, and found that the 
efficiency of transfecting human dermal fibroblasts was improved 25 % with pits of 4µm width and 1µm 
spacing compared to unpatterned substrates16. In contrast, our study investigated a different combination 
of cell type and substrate material (hMSCs on PDMS), and screened an array of nano- and micro-scale 
patterns with a wide variety of geometries. We also observed that both micro-pits (although different in 
size and spacing) and nano-pillars increased non-viral transfection efficiency. This shows that 
topographical influence may be translatable between non-viral transfection of different cell types and 
different substrate materials.  
 Our neuronal transdifferentiation studies started with determining the polyplex dosage that should 
be used based on balancing effects on cytotoxicity and transfection efficiency. We found that a dosage of 
0.25 µg DNA/cm2, with a polymer:DNA mass ratio of 45:1, caused equivalent transfection efficiency and 
resulted in cells with heathier morphology (less blebbing) and higher cell viability compared to higher 
doses. In comparison to studies in literature, our cells experienced lower transfection efficiencies and 
higher toxic effects from transfections with pABOL15, 82. This could have been due to the difference in the 
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type of cells being transfected. Overall net charge of a polymer transfection reagent can affect the 
transfection efficiency of different cell types in different ways120. It has been shown that transfection 
efficiency of hMSCs benefits from polymers with a higher overall net charge than pABOL. Additionally, 
polyplex transfections with higher polymer:DNA ratio can be more toxic to hMSCs compared to other 
cell types which may explain the lower viability we saw in comparison to other studies. Screening of 
topographical influence on neuronal transdifferentiation showed that weak MAP2 expression was present 
in all samples including cells on unpatterned substrates that had not been transfected or exposed to 
neuronal induction media. It was observed that the cells became up to 95-100 % confluent during the 
transdifferentiation protocol, reaching their highest confluence close to the time when media was changed 
from MesenPRO RS medium (hMSC growth medium) to N3 neuronal induction medium. This high 
confluence could have interfered with the transfection of cells therefore hindering their conversion to 
neuronal cells. It is generally recommended that cells be kept below 90% confluent before transfection 
since allowing cells to become highly confluent may slow their growth rate and decrease transfection86, 
117.  Additionally, physical forces from high confluence may have overpowered topographical influences 




To continue the study of topographical influence on non-viral transfection, the six topographies 
that were selected due to their influence on transfection efficiency, cell density, and cell area should be 
studied on single-patterned substrates. A study on single-patterned substrates will give more accurate data 
due to the larger surface areas to analyze per sample providing an opportunity to see if there is any 
statistically significant changes caused by the topographies. On single patterned substrates, the cells can 
also be detached and the percentage of EGFP-expressing cells can be analyzed by flow cytometry. This 
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could be used instead of or in addition to fluorescence imaging analysis and may reduce human error in 
quantifying transfected cells. If statistical significance is found, the relationships between (i) topography 
size, (ii) average cell area, (iii) cell density, and (iv) the relationship between cell density and transfection 
efficiency should be investigated and evaluated with multivariate analysis.   
To continue a fundamental scientific study of topography influence on non-viral neuronal 
transdifferentiation, it could be beneficial to continue studies with a different cell type. Fibroblasts have 
frequently been used for neuronal transdifferentiation studies in literature. Thus, the methods for 
characterizing the success of neuronal induction from fibroblasts are better established, better understood, 
and more consistently accepted. Since hMSCs have been shown to express neuronal markers without any 
intentionally applied neuronal induction, it is more difficult to determine whether neuronal marker 
expression has been induced by the transdifferentiation treatment or was innately present in the hMSCs 
123, 129 124. On the other hand, the innate neuronal marker expression seen in hMSCs may also be seen as a 
predisposition for hMSCs to differentiate into neurons130. Therefore, study of conversion of hMSCs to 
neurons could be useful to develop potential clinical treatment options, and should be further studied prior 
to investigating effects of topography. Since the high confluence reached during our transdifferentiation 
studies could have been a barrier to their success, the initial seeding density could be retuned and tested to 
see if it makes a difference. Other factors that should still be optimized for neuronal transdifferentiation of 
hMSCs are the number of serial transfections used and length of the induction phase. Additionally, 
polymers with a higher overall net charge and polyplexes with lower ratios of polymer:DNA should be 
tested to see if they are a benefit to hMSC transfection and neuronal transdifferentiation. Adjusting these 
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Appendix A: Principal Component Analysis for Studies of Transfection 
on PDMS MARC Chips 
 
A.1.   Introduction 
 
Principal component analysis (PCA) allows us to extract important information from multivariate 
data and represent this information with a set of fewer new variables, called principal components, which 
are linear combinations of the original variables131. If each original variable is thought of as a dimension, 
the goal of PCA is to identify principal components which describe new dimensions that contain the 
largest amount of variation (which can be thought of as information) in the original variables. Here we 
present PCA analysis on data obtained during the study of transfection on PDMS MARC chips (sections 
2.2.8, 2.2.9, 2.3.4, and 2.3.5). 
 
A.2   Methods 
 
PCA was performed, with help from Dr. Marc Aucoin, using the FactoMineR R package. The 
variables considered in this PCA included measurements of normalized transfection efficiency, 
normalized average cell area, and normalized cell density, from five different MARC chips after 
Lipofectamine-mediate transfection which was performed as described in section 2.2.8, as well as 
independent variables describing the features of each topography (height/width aspect ratio, feature 




A.3   Results 
 
The first two principal components explained 58.44% of the variances in our original data. The 
variables factor map, in ,shows the degree of involvement of each of our original variables in principal 
component 1 (Dim 1) and principal component 2 (Dim 2). We see that normalized transfection efficiency 
and normalized average cell area are positively correlated with each other and negatively correlated with 
normalized cell density in these principal component dimensions. Three variables describing the features 
of each topography (height/width aspect ratio, feature spacing, and feature height) are correlated in these 
dimensions, which is not surprising, since our data was made up of multiple observations involving the 
same 16 topographies. Feature width was positively correlated with cell density and negatively correlated 
with normalized transfection efficiency and normalized average cell area in these principal components. 
 
 
Figure 39 Variables factor map. The variables included in this PCA analysis were normalized transfection efficiency 
(Norm_TE), normalized average cell area (Norm_CA), normalized cell density (Norm_CD), feature height/width aspect ratio 
(HW_Ratio), feature spacing (Spacing), feature height (Height), and feature width (Width).  
